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ABSTRACT 
Invasive infections caused by Streptococcus pyogenes, also known as Group A 
Strep (GAS), results in approximately 600,000 deaths annually. With evidence of 
antibiotic-resistant strains of this bacterium on the rise, there is a need for the identification 
of new drug targets to control these infections.  In our approach we target the quinolinate-
salvage pathway (QSP) and the streptolysin S (SLS) biosynthesis pathway. The QSP 
provides a secondary pathway for NAD+ biosynthesis within this organism; the SLS 
pathway leads to the formation of a quorum sensing molecule (SLS). We hypothesize that 
inhibition of the pathways will lead to GAS cell death or will impair the growth of the 
bacterium.   
This dissertation presents results of the functional and structural (using x-ray 
crystallography) characterization of select proteins involved in these pathways.   Highlights 
of the information contained within each chapter are as follows: 
 Chapter 1 provides background information on the QSP and SLS pathways and 
reports current research on both targets. 
 Chapter 2 describes results from structural studies on quinolinate 
phosphoribosyltransferase (spNadC), of the QSP, and shows results from 
functional and structural studies, as well as the first structures of this protein 
and its deletion mutant (spNadC69A).  
 Chapter 3 reports the results from functional characterization of nicotinate 
mononucleotide adenyltransferase (spNadD) of the QSP.  Preliminary
vii 
 structural studies are described. While the protein structure was not yet 
determined, homology modeling was used to provide insights into the proposed 
spNadD structure. 
 Chapter 4 details the functional and structural studies on NAD+ synthetase 
(spNadE) of the QSP. This protein, similarly to NadD, is considered to be a 
good drug target. This chapter describes the first structures of this protein 
determined in GAS. Structural results provide new details for the reaction 
mechanism and the conversion of the substrate (nicotinate adenine dinucleotide 
(NaAD)) into nicotinamide adenine dinucleotide (NAD+) through channels 
identified at the dimer interface of spNadE. 
 Chapter 5 describes results from molecular cloning, isolation, and refolding 
experiments conducted on select SLS biosynthesis proteins:  SagB, SagC, 
SagD, and SagG. Structures of these proteins have not been determined; 
however, molecular cloning experiments for the co-expression of the SagBCD 
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INTRODUCTION TO STREPTOCOCCUS PYOGENES AND THE BIOSYNTHESIS OF NICOTINAMIDE 
ADENINE DINUCLEOTIDE AND STEPTOLYSIN S 
1.1 BACKGROUND AND INTRODUCTION TO STREPTOCOCCUS PYOGENES  
Streptococcus pyogenes, also known as Group A Streptococcus (GAS), is a 
virulent, β-hemolytic, bacterium (1). It is a gram positive, anaerobic, spore-forming 
bacterium that requires nutrient rich environments for optimal growth. This fact makes the 
human body an ideal host for this organism (2). GAS is responsible for the onset of 
infections associated with acute pharyngitis (strep throat), rheumatic fever, scarlet fever, 
toxic shock syndrome, and necrotizing fasciitis (2, 3).  
1.2 GLOBAL IMPACT 
Globally, severe cases of GAS diseases cause over 500,000 deaths per year, which 
places GAS among the ten most common causes of death due to human pathogens (4). In 
less developed countries, specifically Papua New Guinea, Ethiopia, Gambia, and the 
Philippines, invasive GAS infections attribute to approximately 663,000 new cases a year. 
An estimated 160,000 deaths of children, 90 days and younger, make up one third of the 
fatalities (4). In children 15 years and younger, 25% of GAS infections are considered fatal 
and a higher percentage is assumed in undocumented, lesser developed communities (4).  
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The CDC reports that penicillin is still an effective antibiotic for treatment of GAS 
infection, but macrolide, tetracycline, and clindamycin-resistant strains have been 
identified (5). As a result of these findings, new antibiotics must be created to treat these 
resistant strains. This dissertation will explain two new strategies for antibiotic 
development through the use of macromolecular structure-based drug design.  
1.3 THE QUINOLINATE-SALVAGE PATHWAY AND NAD+ BIOSYNTHESIS 
Previous studies have identified that non-specific exotoxin release from GAS 
during infection promotes the activation of interferon-gamma (IFN-) (6). IFN- aids in the 
initiation of tryptophan degradation by monocytes (blood)/macrophages (tissue) by way of 
the kynurenine pathway (6, 7). The end products of this pathway are quinolinic acid (QA) 
and picolinic acid (8).  It could be presumed that there would be increased levels of 
tryptophan degradation and consequently, high levels of quinolinate at the site of infection 
due to immune response. 
GAS has evolved to utilize quinolinate, by the action of the quinolinate-salvage 
pathway (QSP) (1). This ability affords these bacterial species the capacity to use this 
molecule for essential biochemical processes where similar streptococcal species could 
not. Moreover, this adaptation improves GAS's odds of survival and could promote an 
increased virulence when compared to other opportunistic bacteria. Previous studies have 
identified that this pathway is responsible for the utilization of quinolinic acid for the 
biosynthesis of nicotinamide adenine dinucleotide (NAD+) (1). NAD+ is a necessary 
cofactor in the progression of numerous biochemical pathways including glycolysis, 
gluconeogenesis, the citric acid cycle, and the electron transport chain (9). The QSP is 
composed of quinolinate-salvage enzymes (QSEs): quinolinate phosphoribosyltansferase 
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(spNadC), nicotinate mononucleotide transferase (spNadD), and NAD synthetase 
(spNadE), which are collectively responsible for the conversion of quinolinate (QA), 
nicotinate/ niacin (Na), and nicotinamide (Nm) into NAD+ (Figure 1.1) (1).  Specifically, 
for the utilization of QA, NadC is responsible for the conversion of phosphoribosyl 
pyrophosphate (PRPP) and QA into nicotinate mononucleotide (NaMN) (1).  This 
transformation is regarded as the first of three biosynthetic steps in the formation of NAD+ 
(1). The two remaining biosynthetic steps are completed by the action of NadD and NadE 
(1).  NadD is responsible for the conversion of NaMN and Adenosine triphosphate (ATP) 
into nicotinic acid adenine dinucleotide (NaAD) and NadE is responsible for the transfer 
of ammonia to convert NaAD into NAD+ (1, 10). Detailed explanations of QSE activity 
will be explained in their respective chapters. Figure 1.2 provides an overview of the 
reactions catalyzed by the activity of the QSEs. 
1.4 VIRULENCE AND STREPTOLYSIN S BIOSYNTHESIS 
GAS comes in a number of different forms known as serotypes (11).  These 
serotypes (M1-6, M12, M18, M28, M49) are all descriptions of minor genetic variations 
between different strains of GAS (11).  The M designation comes from a product of the 
bacteria’s emm gene referred to as the “M-protein” (11). This protein is a major factor in 
the classification and determination of the virulence of GAS strains.  Other factors include 
streptococcal phospholipase (Sla), which is responsible for promoting adherence of GAS 
to epithelial tissue, streptococcal chemokine protease (SpyCEP), which promotes the 
destruction of interleukin signaling proteins, and immunoglobulin G degrading enzyme 
(Mac1), which is considered to be responsible for antibody degradation (11, 12).  
Furthermore, additional components are streptococcal inhibitor of complement (Sic) and 
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complement 5A peptidase (ScpA), both of which inhibit the activity of the complement 
system, and streptolysin O and S (SLO and SLS) which utilize different mechanisms for 
the lysis of different cell types (11). 
SLS can promote the lysis of red and white blood cells, platelets, and subcellular 
organelles (2, 11).  As a result, GAS gains access to nutrients and evades the body’s 
immune defenses (11). Supplemented by the activity of the virulence proteins described 
above, the immune system manifests the site of infection as a location that looks as if skin 
has been eaten away (11). This description triggered the “flesh-eating bacteria” moniker, 
which is commonly used to describe GAS-related necrotizing fasciitis. 
1.5 RELEVANCE AND HYPOTHESES 
Severe GAS infections, like necrotizing fasciitis, are serious disorders and if left 
untreated can result in gruesome and disfiguring maladies. Severe infections can lead to 
amputations and even death. The general focus of this research resides in understanding 
the means by which GAS promotes infection and contributes to onset of necrotizing 
fasciitis. We presume that the inhibition of SLS and NAD+ biosynthesis can be 
accomplished in order to prevent the progression of infection. 
More specifically, focus of this is work is two-fold:  
1. We are interested in the isolation and structural determination of the proteins 
involved in the activity of the QSP for structure-based inhibitor design. We 
hypothesize that through the inhibition of the QSEs, we can stop bacterial growth.  
2. We are interested in the isolation and structural determination of the proteins 
involved in the biosynthesis and release of Streptolysin S. We hypothesize that 
through the inhibition of proteins involved in the biosynthesis of SLS (SagB-D) 
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and its release (SagG) we can prevent SLS formation, and/or stop the progression 
of necrotizing fasciitis.  
1.6 CURRENT RESEARCH INTO THE QSP AND NAD+ BIOSYNTHESIS 
According to Sorci et al., the QSP operates as a secondary pathway in the formation 
of NAD+ (1). The capacity to express spNadC is the key factor in this process. Genomic 
studies of streptococcal species revealed that nadC is present only in Streptococcus 
pyogenes and Streptococcus pneumoniae and may be related to the increased virulence as 
compared to other, less invasive, streptococci (1).  
In opportunistic streptococcal species, e.g. Streptococcus mutants and 
Streptococcus agalactiae, the process of NAD+ biosynthesis starts at the introduction of 
Na and Nm by the action of the NiaX membrane transporter. NiaX has been previously 
identified as a Na transporter which allows for the transport of Na and Nm across the cell 
membrane into the cytoplasm (1). The next biosynthetic step is the conversion of Na into 
NaMN by the action of nicotinate phosphoribosyl transferase (PncB) (1). Prior to the 
conversion to NamN, Nm must be converted to Na before NaMN biosynthesis can occur 
(1). The conversion is completed by the action of PncA nicotidaminase (PncA) which 
substitutes a hydroxyl group for an amine group before conversion to NaMN by PncB (1). 
As described above, other opportunistic bacteria also encode for NadD which converts 
NaMN into NaAD, and NadE which converts NaAD into NAD+ (1). Refer to Figure 1.8.1 
for a general schematic of this process. 
Avirulent streptococci, e.g. Streptococcus equi and Streptococcus suis, utilize a 
more simplified approach to NAD+ biosynthesis (1). After the transport of nicotinamide 
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riboside (NmR) into the cell by PnuC (an NmR transporter), NadR biochemically modifies 
NmR by operating as a dual-action enzyme. Its first action is to operate as a nucleoside 
kinase converting NmR to nicotinamide mononucleotide (NMN); the second action is as 
an adenyltransferase converting NMN to NAD+ (13).  Figure 1.1 also provides a general 
description of this process. 
What separates GAS and S. pneumonia from the other streptococcal species is their 
ability to utilize a third pathway in combination with the pathway used by opportunistic 
species, described above (1). Both species encode for a NadC and convert QA, which is 
produced during infection, into NaMN for use by NadD, and eventually NadE, for the 
formation of NAD+ (1).  Original speculation was that QA was produced internally by the 
bacteria through aspartate metabolism by L-aspartate oxidase (NadB), and iminoaspartate 
metabolism by quinolinic acid synthetase (NadA) was proposed to lead to formation of QA 
as an end-product (1). It was concluded from knockout studies of PncA and NadC that 
NadC is obtained from the extracellular environment (1).  A simplified description of this 
process can also be found in Figure 1.1. 
In knockout studies of NadD and NadE homologs in Mycobacterium species, it was 
discovered that NadD and NadE were essential for the survival of the species, and their 
loss diminished NAD+ biosynthesis intermediate production and lead to cell death (14)   
In this dissertation, the first published structures of NadC and NadE will be 





1.7 CURRENT RESEARCH INTO STREPTOLYSIN S (SLS) BIOSYNTHESIS 
SLS is a bacteriocin, which is synthesized from the collective activity of the 
streptolysin associated gene operon (sag operon) of the S. pyogenes genome (2, 15). The 
sag operon is a collective of nine open reading frames (ORF's) referred to as sagA – sagI 
(15). All the ORFs encode for proteins necessary for the biosynthesis and export of SLS 
(2). The sagA gene encodes for a 53 amino acid strand (SagA) that acts as a precursor for 
the formation of SLS (2, 15); upon modification by operon proteins, it forms mature SLS 
(2, 16). SagB is proposed to act as a dehydrogenase working in conjunction with SagC and 
SagD, which allows for the withdrawal of necessary hydrogens in preparation for mature 
SLS formation (16). SagC is suggested to operate as a cyclodehydratase that plays a role 
in the conversion of cysteine, serine, and threonine residues of immature SLS into oxazole, 
thiazole, and methyloxazole, respectively, to form mature SLS (16).  SagD is proposed to 
be responsible for the formation of the SagBCD complex and functions in the regulation 
of the complex’s activity (16). SagE has been reported to have two roles: to act as a 
peptidase to promote the removal of an inactive peptide strand of SagA (approximately 23 
amino acids), and to maintain an immunity role in GAS (2).  SagG is proposed to act as a 
membrane-associated protein responsible for the binding of ATP (2).  SagH and SagI work 
in conjunction with SagG, and are considered to be responsible for the release of mature 
SLS into its extracellular environment (2). SagF is believed to be a membrane-associated 
protein, but its function has yet to be defined (2). Figure 1.3 and Table 1.1 provides a 
schematic of the activity of the sag operon, as well as a description of the proposed function 
of each of the proteins involved. 
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At the inception of this project in 2012, the Protein Data Bank (PDB) contained no 
other homologous structures with significant sequence similarity, to SagB, SagC, SagD, or 
SagG, over the entire sequence (Table 1.2). This observation indicates the possibility of 




1.8 FIGURES AND TABLES 
Table 1.1:  The Sag proteins. This table shows proteins encoded by the sag operon, their 
molecular weights, and their proposed function (2).  
 






SagA 53 5  Amino acid precursor of Streptolysin S 
SagB 316 36  Dehydrogenase 
SagC 352 40 Cyclogenase 
SagD 452 51 Linker of SagBC? 
SagE 220 25 Immunity role/ Truncation of SagA? 
SagF 227 26 Membrane associated protein? 
SagG 307 41 ATP Binding Cassette transporter 
(ABC transporter) 
SagH 375 42 ABC transporter 





Table 1.2: Sag proteins and their homologs in PDB.  These are results of a sequence based 
search for proteins similar to SagB, SagC, SagD, and SagG with structures reported to 
Protein Data Bank. The results show very low sequence similarity of SagB-G to proteins 
with known structures (19).  
Protein  # of 
amino 
acids 
The most similar protein 
with known structure as 
identified with BLAST 
Sequence 
identity (%) 
Length of the 
similar protein 
fragment 
(# amino acids) 




PDB code: 4EO3 
18 57 
SagC 352 Escherichia coli MccB 
protein 
 
PDB code: 3H9G 
10 35 
SagD 452 Prochloron sp. 06037A 
heterocyclase TruD 
 
PDB code: 4BS9 
23 103 
SagG 307 Thermotoga maritima 
Abc Transporter Atp-binding 
Protein 
 








Figure 1.1: Integrated pathway for NAD+ biosynthesis in streptococcal species. This 
schematic diagram, adapted from Sorci et al., displays proteins and intermediates involved 
in NAD+ biosynthesis in all Streptococcal species (1). Virulent species of Streptococci, 
specifically S. pneumoniae and S. pyogenes, exhibit the ability to utilize quinolinate as an 
alternate route for nicotinate mononucleotide (NaMN) production which may provide an 






Figure 1.2: The quinolinate-salvage pathway. This figure displays a general description of 








































Figure 1.3: The sag operon. This figure, adapted from Molloy et al., provides an overview 
of the proposed activity of the sag operon during infection. SagA is converted into SLS by 
the collective activity of the the SagBCD complex and SagE (2, 16). SagGHI work together 
to form the proposed ATP binding cassette responsible for the transfer of SLS from the 
intracellular environment to the extracellular environment (2). Once SLS exits the cell it 
can cause the destruction of red blood cells, white blood cells, and platelets. SagF is labeled 
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STRUCTURAL AND FUNCTIONAL STUDIES OF QUINOLINATE PHOSPHORIBOSYLTRANSFERASE 
FROM STREPTOCOCCUS PYOGENES 
2.1 INTRODUCTION 
Quinolinate phosphoribosyltransferase (spNadC) is responsible for the first 
biosynthetic step in a triad of steps related to the formation of NAD+, by way of the QSP, 
in GAS (1).  This enzyme is specifically responsible for the N-nucleoside bond formation 
between PRPP and QA in order to form NaMN (2). This ability to use QA to biosynthesize 
NAD+ enables GAS to use more than one biosynthetic route for NAD+ production. 
Therefore, spNadC is also not considered a drug target, since GAS can also use NiaX 
membrane proteins in order to utilize nicotinate and nicotinamide for NaMN biosynthesis 
(1). The ability to utilize various pathways for NAD+ biosynthesis most likely improves 
survival of GAS during infection (1).  The purpose of this work is to understand the effect 
of spNadC and its role in promoting virulence in GAS. 
The genomic studies presented by Sorci et al. indicated that GAS and Streptococcus 
pneumoniae (S. pneumoniae) are the only two streptococcal species that have the ability to 
produce NadC. It was also suggested that the presence of NadC may be related to the 
increased virulence of S. pyogenes and S. pneumoniae when compared to other avirulent 
and opportunistic streptococcal species (1). Several NadC homologs have their structures 
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determined. They have been identified in eukaryotic species including humans (hsNadC; 
PDB code: 3LAR; 40% sequence identity; RMSD: 1.4Å over 264 Cα atoms) and 
Saccharomyces cerevisiae (scNadC; PDB code: 3C2R; 35% sequence identity; RMSD: 1.7 
Å over 247 Cα atoms). Pathogenic, non-streptococcal species for which a structure of 
spNadC homolog was determined include: Vibrio cholerae (vcNadC; PDB code: 3PAJ; 
45% sequence identity; RMSD: 1.5 Å over 267 Cα atoms), Salmonella enterica (stNadC; 
PDB code: 1QAP, 41% sequence identity; RMSD: 1.9 Å over 262 Cα atoms), 
Mycobacterium tuberculosis (mtNadC; PDB code: 1QPR; 40% sequence identity; RMSD: 
1.3 Å over 272 Cα atoms), Helicobacter pylori (hpNadC; PDB code: 2B7N; 38 % sequence 
identity; RMSD: 1.5 Å over 262 Cα atoms), and Franciscella tularensis (ftNadC; PDB 
code: 3TQV: 36 % sequence identity; RMSD 1.4 Å over 262 Cα atoms). 
According to the Pfam database, NadC is a part of a family of proteins that have an 
 hydrolase fold (3, 4). This fold commonly contains a central parallel  sheet that is 
composed of several beta strands which is flanked by -helices. NadC belongs to the TIM-
phosphate binding superfamily of proteins that are grouped by the presence of a TIM-barrel 
structure containing the same 8  helical/ 8  strand feature described above in the  
hydrolase family (5, 6).  The barrel-type fold corresponds to the C-terminal part of NadC, 
while the N-terminal part of the protein contains an anti-parallel  sheet that is flanked on 
one side by four helices (Figure 2.1). 
This chapter will present the first structural information on native spNadC and 




2.2 RESULTS AND DISCUSSION 
PROTEIN PRODUCTION 
All QSEs were over-expressed and purified in high quantities.  SpNadC isolation 
resulted in approximately 240 mg of the protein per 1L of culture, as measured after an 
immobilized metal affinity chromatography (IMAC) step. Protein purity was confirmed 
using both SDS-PAGE and mass spectrometry.  SpNadC contains a purification tag 
composed of 25 amino acids that encodes for a tobacco etch virus (TEV) cleavage site. 
Cleavage of this tag, with TEV however, was unsuccessful. SpNadC was further purified 
by gel filtration, and the elution profile contained one single peak that corresponds to a 
molecular weight of ~200 kDa. The same results were obtained for both the native and 
mutated protein. Dynamic light scattering was also used to determine the molecular weight 
of NadC69A oligomer in solution. Results from these experiments indicate the molecular 
weight of NadC at 212 ± 80 kDa. These results indicate that most likely in solution spNadC 
forms a hexamer.  
KINETIC DATA 
 According to Sharma et al., mtNadC is proposed to operate in an ordered-sequential 
mechanism with QA binding first and PRPP binding afterward (2) (Figure 2.2). It was 
assumed that spNadC operates according to the same mechanism.  
Following a strategy adapted from Cao et al., an activity assay was conducted for 
native spNadC, as well as spNadC69A (7).  The assay did show activity for both constructs 
as evidenced by increasing absorbance values, at 266 nm, over a 10 minute span. Our 
results indicate that spNadC did not follow classic Michaelis-Menten kinetics, but did show 
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increased NaMN production with increasing PRPP concentrations from 0.2 mM – 1.6 mM. 
An inhibitory result was identified as the QA concentration was increased from 2-20 µM. 
It should be noted that the QA concentration is significantly smaller, in this experiment, 
compared to the PRPP experiments. The inhibitory outcome was also not observed with 
kinetic results from homologs in the literature (2, 7).   
Initial spNadC kinetics studies indicate that this enzyme is very inefficient, which 
is consistent with previous studies (1). However, in the case of the protein used in this 
study, it was observed that increased concentration of QA leads to enzyme inhibition. The 
differences in the results of kinetics studies may be related to the presence of the 
purification tag in the protein that was produced. Recombinant NadC used by Sorci et al. 
contains a short, non-cleavable His×6 purification tag, while the uncleaved purification tag 
used in these studies is 25 amino acids long. It was reported that in some cases the presence 
of the purification tag may significantly affect protein activity and other functional 
properties (8, 9). Assuming that the purification tag impacts the activity of NadC for the 
kinetic studies it will be necessary to produce a recombinant protein without any additional 
amino acids, or with a short purification tag as described previously (1).  
NADCDE ACTIVITY ASSAY 
 Despite the fact that the NadC activity was impaired, it was possible to show that 
NadC, NadD and NadE are able to produce NAD+. The reaction mixture containing all 
QSEs and supplemented with MgCl2, NH4Cl, ATP, phosphoribosyl pyrophosphate (PRPP) 
and quinolinic acid was shown to produce NAD+.  This result prompted us to investigate 
whether the enzymes are present in solution as separate molecular entities or whether they 
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form higher order molecular assemblies. Each of the isolated QSEs were tested on a gel, in 
non-denaturing conditions, to check whether such high order molecular assemblies are 
formed. The results of these experiments clearly indicate that while all NadC, NadD and 
NadE are present in solution in an oligomeric form, the formation of binary or tertiary 
complexes between these enzymes does not take place in conditions that were used for the 
experiment (Figure 2.4). 
THERMAL STABILITY 
Differential scanning fluorimetry studies have shown that native spNadC is more 
stable than the mutant construct. SpNadC remained most stable in conditions at high 
salinity (1 M NaCl) and high pH (pH 9.5) and remained stable until the experiment 
temperature reached 60 °C (Figure 2.6).  SpNadC69A was most stable in high salinity (1 
M NaCl), slightly alkaline (pH 7.5-8) conditions and remained stable up to a temperature 
of 58 °C (Figure 2.7).  It should be noted that while the numerical difference between the 
melting temperatures of each protein is only a difference of 2 °C, while the number of 
conditions that were identified to provide stability up to ≥ 56 °C varied greatly. Native 
spNadC results showed 18 conditions (mostly 250 mM- 1M NaCl, pH 7.0-9.5) with 
melting point temperatures ≥ 56 °C, while spNadC69A only showed stability in only two 
conditions within that range.  
This cost-effective screening technique can also be used for identification of small 
molecular compounds that promote thermal stability of a protein (10, 18). Use of this 
approach resulted in identification of conditions in which protein was more stable, and such 
conditions were used during protein purification and for protein storage. The dialysis buffer 
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conditions that were chosen to store spNadC were: 150 mM NaCl and 0.05 M Tris (pH 
7.5).   
CRYSTALLIZATION 
Native NadC and NadC69A crystals were identified within 48 hours of 
crystallization setup. Crystals were identified in a variety of conditions including Index 
Screen (Hampton Research, Aliso Viejo CA) condition numbers 18, 19, 26, 67, and 81, 
Wizard Classic I (Rigaku, Bainbridge Island, WA) conditions 18, 38, and 48, and Wizard 
Classic II (Rigaku, Bainbridge Island, WA) conditions 15 and 48 (Table 2.1). While crystal 
formation was fast and plentiful, obtaining crystals that diffracted to a resolution higher 
than 4.0 Å was very challenging. Despite the fact that the crystals appeared from various 
solutions their morphology was always the same. The most promising condition (Index 
screen condition # 67: 0.2 M ammonium sulfate, 0.1 M BIS-TRIS (pH 6.5), 25% w/v PEG 
3350) was optimized to improve crystal quality. Optimization eventually led to producing 
crystals that were from 5 to 250 microns in size.  The biggest improvement in 
crystallization was achieved after use of the Hampton Research Additive screen (generous 
gift from Dr. James Sodetz, University of South Carolina) and identification of NaBr as 
the compound that improved crystal quality. The best crystals were grown from the 
solution composed of 0.48 M ammonium sulfate, 0.1 M BIS-TRIS (pH 6.5), 20 % w/v 
PEG 5000 and 1.25 mM NaBr. It was also identified that the NadC and NadC69A crystal 
morphology was temperature dependent. At room temperature the crystals were cube-
shaped, while at 4 ºC the crystals adopted an elongated shape (Figure 2.7). However, the 
change of the crystal morphology did not have any effect on diffraction quality. The largest 
crystals obtained were from a 1.1 M ammonium tartrate condition that produced crystals 
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that were up to 500 microns. Unfortunately, the large volume of the produced crystals did 
not correlate with improved diffraction quality. The most notable results were obtained 
while conducting in situ proteolysis experiments (11). In these experiments, a protease, 
trypsin specifically, was added in nanogram quantities to our protein stock solution directly 
prior to crystal screening preparations. The goal of this procedure was to minimize the 
entropy of the protein surface by cleaving the loop structures. As a result, we hoped to 
improve the probability of crystallization. The result from these experiments also promoted 
an increase in crystals size to approximately 500 microns. Additionally, in situ proteolysis 
crystals were observed to have a “pitted” center (Figure 2.7). The direct cause of this 
morphology is yet to be determined.  
ANALYSIS OF NADC SEQUENCE 
SpNadC contains 299 residues in each chain of the hexameric structure (1794 total 
residues). The NCBI Protein BLASTsearch against homologous proteins found in the PDB 
reveals that this each chain is composed of 2 regions: the dimer interface and the active site 
(5). These results also include predicted residues of the active site (residues in bold are 
highly conserved): T139-K141, H163, R164, D224, S247, G248 and dimer interface: S31, 
T32, E105, R106, T142, L166, S167, M170, K173, N175, H176, A179, and A190 
(5).Conservation of the NadC sequences is shown in Figure 2.8. 
Using the Database of Prokaryotic operons (DOOR2) it was identified that the QSPs 
are not found on the same operon, as it observed in Mycobacterium tuberculosis (12). 
Database results indicate that, in reference to the origin of replication, the nadC reading 
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frame is the farthest upstream of the QSPs. Results from DOOR2 show nadC at position 
180951 to 181823 within the genome. 
STRUCTURAL ANALYSIS 
 Diffraction results were first obtained from spNadC69A crystals grown in the 
following conditions: (1) 1M ammonium phosphate, 0.1 M sodium citrate tribasic/citric 
acid (pH 5.5), 0.2 M sodium chloride (Wizard Classic II, #33, Rigaku Bainbridge Island, 
WA), and (2) 20% w/v PEG 6000, 0.1 M BIS-TRIS (pH 6.4), 0.48 ammonium sulfate, 1.25 
mM sodium bromide. The crystal obtained using condition (1) belong to the cubic system 
and P23 space group, while the conditions (2) lead to orthorhombic crystals with C2221 
symmetry.  The orthorhombic crystals were obtained through optimization of the Hampton 
Research Index screen condition # 67. The native NadC crystals were grown from solution 
containing from 0.48 M ammonium sulfate, 25% w/v PEG 6000 and 0.1 M BIS-TRIS (pH 
6.5). The cubic form contained four protein chains per asymmetric unit and the 
orthorhombic form contained six protein chains per asymmetric unit. Data collection and 
processing details are outlined in Table 2.2. Structure solution and refinement details are 
outlined in Table 2.3.   
OVERALL STRUCTURE 
The first structure to be determined was the structure of the deletion mutant 
(spNadC69A), and the presence of the deletion was discovered during model building. This 
discovery prompted us to produce the native protein (spNadC) with the corrected sequence.  
All determined spNadC structures revealed the presence of hexameric assemblies in the 
crystals. This is in agreement with gel filtration, dynamic light scattering, and native gel 
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results indicating that spNadC is a hexameric structure in solution.  It is assumed the 
hexamer observed in the crystal structure is the same hexamer found in solution. The 
identified oligomeric structure may be treated as a “trimer of dimers”.  The proposed 
substrate binding site is formed by two protein chains that compose the dimer. The area of 
interaction between chains forming the dimer is very large and is calculated to be 2623 Å2, 
as calculated by PDBePISA (13). 
The analysis of the NadC69A structure revealed that the protein fragment, which 
should contain the missing alanine residue, is facing the opening located in the middle of 
the hexamer (Figure 2.10). This protein fragment does not correspond to any secondary 
structural element stabilized by hydrogen bonds, and the deletion does not impact the 
overall structure of the protein. However, the thermal stability of the mutant is decreased 
in comparison with the native protein. It is possible that the shortening of the loop region 
containing A69 results in a strain of the protein backbone that leads to the decreased 
mutated protein stability. It is also possible that the destabilization of the protein is related 
to the fact that omission of the A69 brings together two acidic and negatively charged 
residues (D68 and E70). The lack of any significant structural differences between the 
native and the mutated versions of spNadC and the relatively remote location of the 
deletion with respect to the active site explains why that both versions of protein display 
very similar enzymatic activity. 
ACTIVE SITE 
Structural comparisons of spNadC with seNadC (PDB code: 1QAP) bound to QA 
show that residues T139, R141, K141, H163, and R164 of spNadC are identical with the 
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residues of the stNadC structure. (Figure 2.12). Comparisons with the mtNadC (PDB code: 
1QPR) bound to substrate analogs, phtalic acid (PHT) (QA analog) and PPC (PRPP analog) 
also indicates that the residues involved in QA and PRPP binding are highly conserved not 
only in terms of sequence, but also in their structure (Figure 2.13).  Sharma et al. suggested 
that PRPP is bound to two Mg2+ ions which are considered responsible for stabilizing the 
pyrophosphate region of PRPP (14). However, to date there have been no structures 
determined with PRPP bound. 
In mtNadC residues R105, R139 and R162 (which correspond to R106, R140 and 
R163 in spNadC) are responsible for binding of QA while D173 and R48 residues along 
with a series of coordinated water molecules bind to the phosphate group and metal ion on 
the “pyrophosphate side” of PRPP.  In mtNadC the nitrogen atom from the backbone of 
G249, the carbonyl from A268, the nitrogen atom from G270, and the side chain of H274 
are proposed to be involved in binding of the PRPP C5 phosphate group (14). No 
mechanistic details for this reaction are available, but it is presumed that the nitrogen of 
the pyridine ring of QA initiates a nucleophilic substitution (SN1) reaction on the 
+ C3 of 
PRPP to create the nucleoside bond forming NaMN and PPi (14).  Structural comparisons 
between spNadC and the homologs reported to the PDB also suggests that the QA and 
PRPP binding sites are created from residues from one chain of the dimer and not from the 
interaction of both chains together. Superposition of structures of homologous enzymes 
from Homo sapiens, Salmonella enterica, and Mycobacterium tuberculosis also indicates 




CONCLUSIONS AND FUTURE DIRECTIONS 
The crystal structure of spNadC was determined at 2.85Å resolution. The protein 
forms a hexameric assembly that is present in both solution and crystal state. It is possible 
that the N-terminal purification tag affects protein activity, as well as the quality of the 
crystals. Therefore, the next step in the project will involve generation of a protein 
construct with the purification tag located on the C-terminus. Moreover, lysine residues, 
on the protein surface, will be mutated to alaine to increase the chance of obtaining the 
high quality crystals diffracting to higher resolution. Such crystals are necessary for 
elucidation of details of interactions between spNadC and its substrates. Polyhistidine tag 
removal may also improve enzymatic activity of the enzyme; with the goal of observing 
Michaelis-Menten kinetics in increasing QA and PRPP conditions, as it was observed in 
the case of homologous proteins (2, 7). However, it cannot be excluded that the reaction 
mechanism of spNadC may be different from those reported for the homologous proteins, 
as the sequence identity between spNadC and the proteins that were characterized in terms 
of their enzymatic activity is approximately 40%.   
2.3 MATERIALS AND METHODS 
PROTEIN PRODUCTION AND CRYSTALLIZATION 
Genomic information on the QSEs were obtained from the Uniprot (15).  Synthetic 
genes with optimized codons were produced by DNA 2.0 (Menlo Park, CA) and introduced 
into a vector bearing kanamycin-resistance pJexpress411. Each of the QSEs were designed 
to contain an N-terminal purification tag (MHHHHHHSSGVDLGTENLYFQS↓GSG). The 
purification tag includes a TEV-cleavage site (marked with an arrow). Each of the plasmids 
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were introduced into competent BL21 (DE3) E. coli (New England Biolabs, Ipswich, MA), 
and the cells were made competent using calcium chloride (17).  The plasmids were 
introduced using the heat/ cold shock method for bacterial transformation (18). Upon 
transformation, the cells were grown on Luria Broth (LB) agar plates supplemented with 
kanamycin, for 12 hours at 37 °C. Observations made the following day identified greater 
than 100 pearl-white colonies. A single colony was transferred and cultured in 5 mL of 
kanamycin-infused LB broth for 12-16 hours at 37 °C. After the 12-16 hour incubation, a 
portion of the cultures were stored in a 40 % glycerol/LB media solution and kept at -80 
°C. The remaining culture was used for transformation confirmation by DNA sequencing. 
As it was previously mentioned, during model building it was discovered that the synthesis 
of nadC gene resulted in omission of a codon and production of the spNadC69A deletion 
mutant. The gene was re-synthetized, to insert the alanine codon into the DNA sequence, 
by Genscript (Piscataway, NJ).  
Overnight preparatory cultures of transformed BL21 (DE3) E. coli (New England 
Biolabs, Ipswich, MA) were transferred into 1L of LB media, and allowed to rotate, at 250 
RPM, for approximately 2.5 hours at 37 °C.  When optical density (OD600) was achieved, 
between 0.8 and 1.0, 200 µL of 1 M IPTG was added to promote protein over-expression 
as outlined by Sorci et al. (1). The induced culture temperature was dropped to 18 °C and 
allowed to rotate at 250 rpm for 12-16 hours (1).  
Upon completion of the 12-16 hour culture, the culture media was spun at 10524 g 
for 20 minutes at 4 °C using the Beckman Coulter Avanti J265 XPI centrifuge (Brea, 
CA).The resulting cell pellet was weighed and stored at -80 °C. In preparation for isolation, 
the cell pellet was re-solubilized in buffer containing: 500 mM NaCl, 150 mM Tris buffer 
28 
 
(pH 7.5), 5 mM 2-mercaptoethanol, and 1x concentration of protease inhibitors (Thermo 
Scientific, Waltham, MA). The cells were lysed, on ice, using the Branson 450 Sonifier. 
Each cell pellet was sonicated in 10, 30 second, cycles, which included a 1 minute break 
between cycles. The cell lysate was separated into soluble and insoluble fractions using the 
Beckman Allegra X30 R centrifuge, at 3849 g, for 20 minutes. The soluble fraction was 
decanted and centrifuged again using the Beckman Avanti J265 XPI centrifuge at 32264 g 
for 20 min, at 4 °C. The soluble fraction was used for protein isolation, using the 
immobilized metal affinity chromatography and Ni-NTA resin (Qiagen, Hilden, DE), 
while the insoluble fraction was kept at -80 °C for analysis. The protein was eluted from 
the column using an imidazole gradient of 5 mM, 60 mM, 250 mM, and 500 mM. Purity 
of protein samples was confirmed by SDS-PAGE. The eluted protein solution was allowed 
to dialyze overnight, at 4 °C, in buffer containing: 50 mM Tris, 150 mM NaCl, and 5 mM 
2-mercaptoethanol. The dialyzed protein solution was further purified by size exclusion 
chromatography. All size exclusion experiments were conducted on the AKTA™ Pure 
(General Electric, Piscataway, NJ) using the Superdex 200 HiLoad 16/60 column. Buffer 
conditions for these experiments were the same as for the dialysis buffer. The fractions 
representative of the protein of interest were concentrated, divided into 1 mL aliquots, and 
stored at -80 °C. 
All initial crystallization experiments were performed using the sitting-drop vapor-
diffusion method. The initial screening utilized the 96 well Original Intelli 96-2 plates (Art 
Robbins Instruments, Sunnyvale, CA). The well contained 80 µL of screening solution, 
and the drops were formed by mixing of 1 µL of protein solution and 1 µL of screening 
solution. Several commercial crystallization screens, Wizard Classic 1-4 (Molecular 
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Dimensions/Rigaku, Altamonte Springs, FL) and Index (Hampton Research, Aliso Viejo 
CA) for example, were used in the initial search of crystallization conditions.  
Optimization experiments used both sitting and hanging drop techniques. Sitting-
drop experiments used the 24-well Cryschem sitting-drop plate (Hampton Research, Aliso 
Viejo CA). Each well contained 500 µL of crystallization solution, and the sitting-drop 
contained 3 µL of 2 mg/mL protein and 3 µL of well solution. Hanging-drop experiments 
utilized the Qiagen EasyXtal 15 well tool (Hilde, DE). The well contained 150 µL of 
crystallization solution, and the screw cap contained 2 drops, 6 µL each, in the same 
solution mixture as in the sitting-drop experiment Most of the crystallization experiments 
were conducted at 25 °C, with fewer experiments conducted at 18 °C and 4 °C. 
DYNAMIC LIGHT SCATTERING 
Dynamic Light Scattering (DLS) was used to characterize a quaternary structure of 
protein in solution. For DLS experiments, 2 mL of 2 mg/mL QSE was dialyzed for 12 
hours in the dialysis solution described above. After dialysis, the QSEs were diluted to 0.2 
mg/mL, using the dialysis buffer, and the sample was analyzed using the experimental 
procedure for instrumental analysis, as outlined by protocol prepared by Malvern 
(Worcestershire, UK) for the Zetaseizer ZS90. 
DIFFERENTIAL SCANNING FLUORIMETRY 
Differential Scanning Fluorimetry (DSF) was used for the determination of protein 
thermal stability as well as the determination of the small molecular compounds influence 
on protein stability (19). SYPRO-Orange is an additive that produces fluorescence when 
bound to hydrophobic residues during protein denaturation (19, 20). In this experiment, 
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proteins are heated incrementally, and the determination of their thermal stability is 
indicated by the temperature at which they fluoresce.  
Protein stability was initially checked by testing 96 different buffer conditions using 
an in-house pH and salinity screen. The screen was designed to increase pH from 4.0 to 9.5 
and increase NaCl concentrations from 0.0 to 1.0 M using a 96-well arrangement (19). A 
chart displaying the buffer strategy is outlined in Figure 2.13.  Sypro-Orange (Life 
Technologies, Grand Island, NY) was first diluted 1:1000 in 1 mL of the QSE stock, at 2 
mg/mL, and the protein solution was placed on ice. Ninety-six buffer solutions, increasing 
in pH and NaCl concentration, were then added to their respective wells using the Biorad 
(Hercules, CA) Hardshell 96-well PCR plate. Figure 2.14 provides a schematic describing 
buffer conditions for each well. Using the BioRad (Hercules, CA) CFX96 real-time PCR 
machine, a computer protocol was designed to vary the temperature of each well by 2 ºC/ 
min from 30 ºC to 90 ºC.  Melting temperatures for the QSEs were determined by 
fluorescence. Derivative results for protein melting points were calculated by the Bio-Rad 
CFX96 software package.  This protocol was adapted by Dr. Nicholas Mank (unpublished) 
from the original work of Niesen et al. (19). The stability of QSEs was also tested in the 
presence of various small molecular compounds. Experiment preparation was the same as 
described above. All small molecule screening conditions were made soluble in aqueous 







The enzymatic activity of spNadC was determined by a method outlined in the 
study of a homologus quinolinate phosphoribosyl transferase in Salmonella tyhphimurium 
(7). Briefly, activity reaction conditions, at a final volume of 1 mL, contained 50 mM 
HEPES (pH 7.5), 6 mM MgCl2, 200 µM PRPP, 300 µM QA, and 20 µg of NadC. The 
reaction time was 10 min per experiment. Reaction conditions for kinetic experiments 
which involved testing the effect of increasing PRPP on the activity of spNadC maintained 
the same activity assay concentrations, described above, with increasing amounts of PRPP 
at the following concentrations:  200 µM, 400 µM, 600 µM, 800 µM, 1 mM, 1.2 mM, 1.4 
mM, and 1.6 mM. The above experiment was repeated with increasing amounts of QA at 
the following concentrations: 2 µM, 4 µM, 6 µM, 8 µM, 10 µM, 12 µM, 14 µM, 16 µM, 
18 µM, and 20 µM. NaMN detection was measured using the Nanodrop 2000c (Thermo 
Scientific, Waltman, MA) at 266 nm. Each experiment was done in triplicate, at 1 mL, 
using a quartz cuvette, and NaMN biosynthesis was detected at 266 nm.  
 In a separate assay, biosynthesis of NAD+ was confirmed, at 340 nm, with the use 
of all of the QSEs in one reaction solution. The reaction was conducted at 1 mL in a quartz 
cuvette. The reaction solution contained: 50 mM HEPES (pH 7.5), 6 mM MgCl2, 20 mM 
KCl, 10 mM NH4Cl, 2 mM ATP, 0.2 mM phosphoribosyl pyrophosphate (PRPP), 0.36 
mM quinolinic acid (QA), 2 µg bovine serum albumin (BSA), 1 % ethanol, 4 µg NadC, 4 
µg NadC, 4 µg NadE, 10 µg alcohol dehydrogenase (ADH). The activity assay was run for 
10 min. The success of this assay lead us to attempt a supplemental assay to determine the 
effect of increasing NadC on the rate of NAD+ formation, although no conclusive results 
have been obtained to date.  
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DATA COLLECTION AND PROCESSING 
Prior to the diffraction experiments spNadC and spNadC69A crystals were cryo-
cooled. 10 % glycerol was used to cryo-protect the crystal grown from ammonium 
phosphate, and no cryoprotectant was used for other crystals. Data was collected at the 
Advanced Photon Source at Argonne National Laboratory in Lemont, IL.  The data from 
the NadC69 crystals were collected at Sector 22 belonging to the Southeast Regional 
Collaborative Access Team (SER-CAT); beamlines 22 BM and 22 ID. Data for native 
spNadC was collected at Sector 19 belonging to the Structural Biology Center; beamline 
19 BM. All data collection was performed at 100 K. Data processing was performed using 
HKL-2000 (21) and the details of the diffraction experiments are shown in Table 2.2. 
STRUCTURE DETERMINATION AND VALIDATION 
For each of the spNadC and spNadC69A structures HKL-3000 and MOLREP (21, 
22) were used for structure determination. Both of the spNadC69A structures were solved 
prior to the spNadC structure and molecular replacement was used for phasing. The P23 
spNadC69A structure was solved first using the Homo sapiens NadC homolog (PDB code:  
4KWV) as a starting model. The model of spNadC69A cubic form was used as a starting 
point for determination of the orthorhombic C2221 form. Determination of native spNadC 
structure was done by Fourier synthesis using the spNadC69A C2221 structure to calculate 
phases. All structures were refined using HKL-3000 and Refmac (23), and models were 
updated and validated using COOT (24). Final validation was done using Molprobity (25) 
and CheckMyMetal (26). All of the spNadC and spNadC69A structures and structure 
factors were deposited into the Protein Data Bank (PDB) and were given the accession 
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codes 5HUL (spNadC69A - P23), 5HUO (spNadC69A - C2221), and 5HUP (native 
spNadC). Summary information on model refinement and validation is included in Table 
2.3.  
OTHER COMPUTATIONAL METHODS 
Other Computational methods include: the DALI database for protein structural 
comparison studies (27); Xtalpred, for predicative studies on the likelihood of 
crystallization of all of the QSPs (28); Protparam, for the determination of predicted 
chemical parameters for all of the QSPs (29).  PHYRE2 and SwissModel were used to 
make predictions on the structural parameters for each of the QSPs through structural 
homology calculations (30, 31). Pymol was used for structure structural studies and cartoon 
and surface representations throughout this dissertation (32).  Clustal Omega and ESPript 
was employed for sequence alignment and secondary structure studies (33, 34). PDBePISA 
was applied for the calculation of structural and thermodynamic parameters for each of the 
QSPs (35). Consurf was used for the determination of residue conservation for all of the 
QSPS, as well as provided structural representations for this conservation for display in 
Pymol (36).  
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2.4 TABLES AND FIGURES 
Table 2.1: Crystallization conditions for spNadC and spNadC69A identified during an 
initial screening. 
Screen Condition # Condition contents 
Index 18 0.49 M sodium phosphate monobasic monohydrate, 0.91 M 
potassium phosphate dibasic (pH 6.9) 
 19 0.056 M sodium phosphate monobasic monohydrate, 1.344 M 
potassium phosphate dibasic (pH 6.9) 
 26 1.1 M ammonium tartrate (pH 7.0) 
 67 0.2 ammonium sulfate, 25 % w/v PEG 3350, 0.1 M BIS-TRIS 
(pH 6.5) 




18 1.0 M potassium sodium tartrate, 0.2 M sodium chloride, 0.1 
M imidazole (pH 8.0) 
 38 0.2 M lithium sulfate, 1.0 M potassium sodium tartrate, 0.1 M 
CHES (pH 9.5) 
 48 20 % w/v PEG 1000, 0.2 M zinc acetate, 0.1 M sodium 
acetate/ acetic acid (pH 4.5) 
Wizard 
Classic II 
15 1.26 M ammonium sulfate, 0.1 M HEPES (pH 7.5) 




Table 2.2: Summary of spNadC and spNadC69A data collection and processing. 
 
  
Protein spNadC69A spNadC69A spNadC 
PDB accession code 5HUL 5HUO 5HUP 
Diffraction source APS (21 ID) APS (22 BM) APS (19 BM) 
Wavelength (Å) 1.000 1.000 1.000 
Detector Rayonix 
MX300HS 




380 280 270 
Rotation range per image (°) 0.5 1.0 0.5 
Total rotation range (°) 100 200 100 
Exposure time per image (s) 1  1  1 
Space group P23 C2221                  C2221 
a, b, c (Å) 179.6, 179.6, 
179.6                 
106.2,186.3, 221.9                 108.2, 189.0, 
222.4 
Resolution range (Å) 40- 2.85 
(2.95- 2.85) 




σ Cutoff -3  -3  -3  
Total No. of reflections 44917 (2166) 54566 (2658) 26521 (1389) 
Completeness (%) 99.8 (99.5) 100 (100) 
 
90.3 (95.2) 
Redundancy 4.7 (4.6) 8.4 (8.5) 3.8 (3.9) 
〈I/σ(I)〉 24.1 (2.0) 14.6 (2.3) 7.9 (1.8) 
Rr.i.m. 0.129 (0.990) 0.162 (0.958) 0.140 (0.790) 
Rp.i.m. 0.055 (0.434) 0.056 (0.331) 0.071 (0.389) 
Overall B factor from Wilson 
plot (Å2) 
84.6 64.6 45.3 
CC ½ (0.573) (0.791) (0.729) 
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Table 2.3. Summary of spNadC and spNadC69A structure refinement statistics. 
Protein NadC69A NadC69A Native NadC 




50- 3.45 (3.54- 
3.45) 
Completeness (%) 99.72 (99.6) 99.92 (100) 82.40 (72) 
 Cut-off 0 0 0 
No. of reflections, 
working set 
42638 51691 23687 
No. of reflections, test 
set 
2268 2768 1271 
Final Rcryst 0.222 0.220 0.303 
Final Rfree 0.246 0.258 0.348 
No. of non-H atoms 8629 13034 12565 
Protein 8517 12798 12454 
Ligand 16 20 17 
Solvent 96 216 94 
R.m.s deviations    
Bonds (Å) 0.012 0.012 0.011 
Angles (°) 80 53 84 
Average B factors (Å2)    
Protein 81.5 54.0 88.3 
Ligand 86.1 85.1 85.1 
Ramachandran plot    
Most favored (%) 96.6 96.7 93.5 
Allowed (%) 100 99 99.5 
Visible Residues    
Chain A 6- 288 6- 288 6- 288 
Chain B 6- 288 6- 288 6- 288 
Chain C 6- 288 6- 288  8- 289 
Chain D 5-288   
Chain E  6- 288 6- 289 
Chain F   5-289 






Figure 2.1: The spNadC monomer. This is a cartoon representation of a single chain of 
spNadC shown in three different orientations. The N-terminus is shown in black, the C-






Figure 2.2: Cleland diagram describing ordered-sequential reaction.  This diagram shows 
an overview of an ordered-sequential reaction proposed for spNadC as based on Cao et al. 
(7, 35). This schema is shown using the Cleland notation (35). “A” corresponds to PRPP; 






Figure 2.3: Native gel electrophoresis of spNadC, spNadD, and spNadE. These results are 
of the native gel electrophoresis for the experiments testing formation of higher order 






Figure 2.4: DSF experimental outline. This outline displays the buffer conditions within 
the 96-well plate for DSF/ Thermal stability experiments. These conditions were used for 






Figure 2.5: Thermal stability results for spNadC69A. This chart depicts exemplary results 





Figure 2.6: Thermal stability results for spNadC. This chart depicts results of a single 





Figure 2.7: SpNadC crystals with various morphologies. These figures show wild-type 
spNadC crystals with different morphologies obtained in various conditions. The leftmost 
picture displays the “pitted” center identified in in situ proteolysis conditions, the middle 
figure displays the results of crystallization at 4 ºC and formation of an elongated spNadC 
crystal. The right figure displays the most common spNadC crystal morphology observed 





Figure 2.8: SpNadC sequence alignment. Sequence alignment for spNadC and homologous 
proteins which have their structures determined. The alignment was done using the ESPript 
3.0 and CLUSTALW. SpNadC homologs originate from Vibrio cholerae (vcNadC), 
Salmonella enterica (stNadC), Mycobacterium tuberculosis (mtNadC), Homo sapiens 
(hsNadC), Franciscella tularensis (ftNadC), Helicobacter pylori (hpNadC), and 











Figure 2.10: SpNadC69A structure. Cartoon representations of the hexameric assembly of 
NadC69A
 with (left) and without (right) secondary structure elements. Areas highlighted 
in yellow define the locations of D68 and E70 residues. Areas highlighted in red are 












Figure 2.12: SpNadC with modeled inhibitor molecules. This cartoon representation shows 
structural features of spNadC. Section “A” is representative of the complete spNadC 
hexameric assembly; section “B” shows an spNadC dimer magnified and superposed with 
a homologous dimer from mtNadC (PDB code: 1QPR) to show the predicted site active 
site for spNadC (mtNadC is also hexamer); section “C” shows the magnified active site 
and displays residue similarities between each structure. The residue numbers describe the 









Figure 2.13: SpNadC with modeled substrate. This cartoon representation shows structural 
features of spNadC. Section “A” is representative of the complete spNadC hexameric 
assembly; section “B” shows an spNadC dimer magnified and superposed with a 
homologous dimer from stNadC (PDB code: 1QAP) to show the predicted site active site 
for spNadC (stNadC is a dimer); section “C” shows the magnified active site and displays 
residue similarities between each structure. The residue numbers describe the amino acids 







Figure 2.14: Putative spNadC QA binding pocket. This figure shows a surface 
representation of spNadC (left) and hsNadC (PDB code: 5AYY) (right) and the QA binding 
pocket. For spNadC, the position of the QA was modeled using the hsNadC structure. QA 
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STRUCTURAL STUDIES OF NICOTINATE MONONUCLEOTIDE ADENYLYLTRANSFERASE 
(NADD) OF THE GAS QUINOLINATE-SALVAGE PATHWAY 
3.1 INTRODUCTION 
SpNadD is the second of the trio of proteins, within the QSP, that is responsible for 
the conversion of NaMN and ATP into NaAD (1) (Figure 3.1). According to the Database 
for Essential Genes (DEGG) and available literature, the expression of the nadD gene is 
integral for the survival of various pathogenic bacteria (1, 2).  Moreover, the fact that 
human homolog of NadD and spNadD have only 20% sequence identity makes the S. 
pyogenes protein an attractive target for development of antimicrobial compounds. NadD 
is a member of the nucleotidyl transferase superfamily of proteins (3). A signature 
trademark of this superfamily is the presence of a (T/H)XGH motif that has been observed,  
to play a part in the binding of ATP within the active site (Figure 3.2) (4).  Other members 
of this superfamily include adenyltransferases, tRNA synthetases, panthothenate 
synthetase, ATP sulfurylases and cytidylyltransferase. As reported by Interpro, a common 
characteristic feature of this superfamily is the presence of the Rossman-like // 
sandwich fold (5).  Despite the fact that NadD proteins have very similar overall fold they 
may form different oligomeric structures. For example these proteins were reported to have 
dimeric Staphylococcus aureus NadD (PDB code 2H29), tetrameric Bacillus subtilis NadD 
(PDB code: 1KAM) or hexameric Homo sapiens NadD (PDB code: 1KR2) quaternary
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 structures (4, 6, 7).  The Escherichia coli homolog of NadD (ecNadD; PDB code: 1K4M), 
has been observed to come in two forms: monomeric in the apo, and trimeric in the 
substrate-bound form (9). However, the trimeric form has only been observed in crystal (9) 
(Figure 3.3). 
This structure of spNadD has yet to be determined. This chapter will present results 
of protein production, crystallization, thermal stability, initial structural results, and 
homology modeling. 
3.2 RESULTS AND DISCUSSION 
PROTEIN PRODUCTION  
Recombinant spNadD was successfully expressed and isolated at a yield of ~50 
mg/ L of culture.  SDS-PAGE results indicated that isolation of spNadD was approximately 
95% pure after gel filtration. Polyhisitdine tag cleavage experiments were successful for 
spNadD, and it was the only QSP for which the purification tag could be removed.  Results 
of gel filtration experiments suggests that spNadC form a trimer in solution.  These results 
were consistent with the dynamic light scattering and native gel electrophoresis 
experiments. The molecular weight of spNadD, as determined by DLS, was approximately 
72 (± 9.7) kDa, while the molecular weight of a single spNadD chain is 24 kDa. Native 
Gels tested to determine QSE complex formation also indicate that spNadD is trimer and 






Analysis of the protein thermal stability in solutions with varying pH and NaCl 
concentration showed that spNadD was most stable in conditions with high salinity and 
alkaline pH (Figure 3.4).  There was no significant difference in the thermal stability of 
spNadD with the purification tag compared to the protein with the cleaved tag (Figure 3.5).  
The thermal stability studies revealed that various compounds may increase the 
melting temperature of spNadD. For example, alanine, aminobiphenyl (in 15% DMSO), 
cysteine, ferrous sulfate, malate, sodium pyruvate, and succinate promoted NadD stability 
up to 60 °C (relative to the control conditions in which protein melted at 50 °C). Cadmium 
chloride, Fast violet B salt, magnesium chloride, and sodium bromide promoted stability 
up to 62 °C. Potassium tetrachloroplatinate, provided the greatest amount of stability at 64 
°C (Figure 3.6). 
CRYSTALLIZATION 
Crystals of spNadD with and without purification tag may be obtained using the 
following conditions: 1) 0.1 M succinic acid, 15% w/v PEG 3350 2) 20% w/v PEG 3350 
and 3) 20% w/v PEG 3350, 0.2 M MgCl2, 0.1 M Tris (pH 8.5) (Figure 3.7).  Crystals for 
this protein, in all conditions, have long crystallization periods ranging from 2 weeks to 4 
months.  Crystals in the succinate condition produced irregularly-shaped clusters. Crystals 
in the conditions in 2 and 3 produced long, hexagonal prism-shaped crystals. Crystals 
obtained using condition #3 produced the best diffraction data.  Various attempts to 
improve quality of the crystals failed. For example, attempts to crystallize protein in 
presence of substrate and substrate analogs were unsuccessful.  Addition of the compounds 
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that were identified to increase the thermal stability of NadD also did not improve the 
quality of crystals.  The protein was successfully modified using the reductive methylation 
of lysine. However, the methylated protein could not be crystallized. Work is currently 
being conducted to further optimize the conditions for crystal growth and identify solutions 
that would promote crystal growth when the protein is in complex with its substrates. 
ANALYSIS OF NADD SEQUENCE 
According to the DOOR2 the nadD gene is located further downstream from nadC 
gene, with respect to the origin, at position 275946-276578. SpNadD is the smallest of the 
QSPs with only 210 residues in the polypeptide chain. Sequence analysis results suggest 
that the areas with the highest sequence conservation, between NadD homologs with 
known structures, include residues: 30-44, 60, 78-81, 103-110, 128, 131, 138, 144, 154, 
155, 182, and 199, 202, 208, and 209. Most of the conserved residues between 30- 138 are 
affiliated with the active site. According to Uniprot and Pfam spNadD contains the CTP 
transferase-like domain that is composed of residues 28-183. NCBI Protein BLAST results 
provide predicted locations of two major segments within the sequence: the active site 
(substrate stabilizing) segment, and the (T/H)XGH motif.  The sequence analysis suggests 
that the active site residues include:  L29, G30, G31, N32, H37-H40 (T/H) XGH motif), 
V43, P64, S105, Y106, T107, F125, I127, G128, D130, M131, D138, W138, H139, Q154, 
R155, and I176. The (T/H)XGH motif residues in spNadD include H37, N38, A39,  and 
H40. The residues are highlighted in bold to indicate that they are highly conserved. Refer 
to Figure 3.8 for spNadD sequence alignment and residue conservation results with NadD 
homologs with known structures. 
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INITIAL STRUCTURAL ANALYSIS 
CRYSTAL STRUCTURE 
The best crystal of spNadD with cleaved purification tag diffracted only to 8.5 Å 
resolution.  The low resolution data suggests that the protein crystallized in a monoclinic 
system and P21 space group. The unit cell parameters were identified as: a =104Å, b =103 
Å, c =114 Å,  =108º. Analysis of the probable solvent content using the Matthews 
coefficient indicates that between 4 to 12 copies of spNadD are present in the asymmetric 
unit (10). Gel filtration analysis, native gel analysis, and DSL results indicate that spNadD 
is a trimer. Therefore, taking into account information on the crystal symmetry, the 
oligomeric state of the protein and the solvent content most likely the unit cell contains 6, 
9 or 12 protein chains in the asymmetric unit.  
HOMOLOGY MODELING AND ANALYSIS OF THE MODEL 
The PHYRE2 server was used to calculate homology models for the spNadD. 
PHYRE2 reports the model results with structural quality parameters for confidence, 
coverage, and identity. PHYRE2 defines confidence as “the probability that your (input) 
sequence and the template are homologous”. The top four homology models used as 
templates were from Bacillus anthracis (baNadD; PDB code: 3E27), Bacillus subtilis 
(bsNadD; PDB code: 1KAM), Staphylococcus aureus (saNadD; PDB code: 2H29), and 
Pseudomonas aeruginosa (paNadD; PDB: 1YUN).  Each of the homologs had confidence 
values of 100%, coverage of ≥ 88%, and identity of ≥ 33%. Cartoon representations of 
these structures are shown in Figures 3.9 and 3.10. RMSD values between the NadD 
homology model, built from a Bacillus anthracis template (PDB code: 3E27), against the 
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top four homology models were: 1.2 Å for the saNadD model, 1.5 Å for the ecNadD model, 
1.5 Å for the bsNadD model and 1.8Å for the paNadD model. Structural comparisons show 
the greatest variability in the orientation of the loop regions, but the the secondary structure 
elements forming structure the core of the protein are the same in all generated models.  
NADD ACTIVE SITE PREDICTION 
To gain insight into the active site location we compared structures of spNadD 
homologs (saNadD, baNadD, mtNadD and bsNadD). It was observed that each monomer, 
shows NaAD bound in similar locations. The adenylate moiety of NaAD is observed to 
bind closer to the N-terminus which allows for stabilization by the highly conserved 
(T/H)XGH motif, described above. For the spNadD model and the homologs the motif is 
commonly found with in the first 20 residues, from the N-terminus of the structure. 
Specifically, the motif for spNadD is “HNAH”, “HTAH” for saNadD, “HNGH” for 
bsNadD, “HYAH” for saNadD, and for baNadD and mtNadD for it is “HGYH”. The 
notable aspect of this motif is the orientation of both of the histidine residues, as they are 
always oriented toward the adenlylate, located deep within the site. The acidic residues of 
the motif are oriented toward the protein surface. Refer to Figure 3.11 and 3.12 for a 
cartoon depiction of the binding pocket in open and closed conformations. Superposition 
results for spNadD homology model versus the structural homologs reveal that there is 
residue consistency, compared to spNadD residues described in Section 3.2.4, between 
structures with variability in residue orientation dependent upon what is in the active site. 
The orientation of the baNadD structure (PDB code: 3HFJ) with the inhibitor-bound does 
show a major difference in residue orientation, but the binding site for the inhibitor 
molecule is in a different location than the NaAD site. Contrary to this exception, the 
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remaining structure results give confidence that the homology model could be an accurate 
depiction of this protein and it is assumed that spNadD will contain the same active site 
location. 
CONCLUSIONS AND FUTURE DIRECTIONS 
NadD continues to be the most elusive of the QSPs for structure determination, yet 
may be one of the most critical primary targets for inhibitor development (8). Experimental 
data has determined is that the protein is extremely stable, but difficult to crystalize 
efficiently. Similar to results obtained by Zhang et al., from a homologous NadD construct 
from E. coli, show that it can take weeks to grow crystals (9). Difficulties with 
inconsistency, with manual preparation, can make it a challenge to quickly observe changes 
to crystal formation, and optimize in an efficient manner. To overcome this two strategies 
were employed to decrease general entropy of the protein in order to improve the likelihood 
of crystallization. In first strategy, we decided methylate the lysine residues in all of the 
QSPs in order to improve the probability of crystallization and/or change crystal 
morphology in order to improve diffraction for higher resolution results. The second 
strategy targeted the mutation of the lysine residues to improve the formation of crystal 
contacts. We utilized the SERp server (UCLA) to identify target lysine residues for 
mutation in order to decrease overall protein entropy (11). Results from the server indicate 
that lysine residues 44-45 and residues 210-211 (in DNA 2.0 optimized sequence) were 
prime targets for mutation (11).  Using the NCBI Protien BLAST server, these residues 
were also determined to not interfere with residues involved with active site binding (11, 
12, 13). Future experiments will utilize molecular cloning to mutate lysine residues into 
alanine residues thus creating three NadD mutant constructs. These NadD constructs will 
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have mutations at residues 44-45 only, 210-211 only, and a double mutant will have 
substitutions at both sites at both sites.  By decreasing entropy we hope to create protein 
constructs that will afford a more efficient means of crystal formation, for higher quality 
crystals for eventual x-ray analysis.  
3.3 MATERIALS AND METHODS 
PROTEIN PRODUCTION AND CRYSTALLIZATION 
All protocols for protein production, isolation, and crystallization experiments are 
consistent with the experimental protocol outlined previously in Chapter 2, pages 27-30. 
In addition, for the purpose of crystallization spNadD was methylated. The reductive 
methylation of lysine was performed using a protocol outline previously (14). Briefly, each 
the QSPs were stored at -80 °C in 2 mg/mL concentrations for crystallization and were 
thawed, on ice, prior to the methylation experiment. The protein solutions were initially 
diluted two-fold in dialysis buffer (50 mM Tris (pH 7.5), 150 mM NaCl, and 5 mM 2-
mercapto-ethanol).  The solution was then placed in an ice bath for 30 min. After ice bath 
incubation, 50 µL of 85 mM formaldehyde (diluted from 1 M stock in dialysis buffer) was 
added to the protein solution and was gently mixed.  Afterward 25 µL of 1 M Borane-
Dimethylamine (BDA) complex was added to the solution, mixed gently and returned to 
the ice bath for two hours. After the two hour incubation, the formaldehyde and BDA was 
added again to the protein solution at the volumes described above, and was returned to the 
ice bath for an additional hour. Upon completion of the hour long incubation 20 µL more 
of BDA was added and left at 4 °C for 12-16 hours. After the overnight incubation, 1-2 mg 
of solid glycine was added and was placed in the ice bath for an additional hour. Upon 
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completion the solution was concentrated and buffer exchanged in preparation for MALDI 
analysis for confirmation of experiment success.    
DYNAMIC LIGHT SCATTERING 
 All protocols for dynamic light scattering experiments are consistent with the 
protocols outlined previously in Chapter 2, page 30. 
DIFFERENTIAL SCANNING FLUORIMETRY 
SpNadD thermal stability experiments were conducted using the Differential 
Scanning Fluorimetry strategy outlined in Chapter 1, pages 30-31.  
The thermal stability studies of spNadD in the presence of various small molecular 
compounds were performed using the same approach as in the case of the pH vs. salinity 
studies. The difference in the protocols was that the pH and salinity buffer solution was 
exchanged with 10 µL of buffered small molecule solutions (0.05-0.1 M Tris pH 7.5). 
Contents of each of the 384 conditions are contained in Appendix I. This protocol was 
prepared by Dr. Nicholas Mank, which was adapted from the original work of Niesen et 
al. (15). The conditions were prepared by an undergraduate volunteer Vincent Klapper. 
DATA COLLECTION AND PROCESSING 
SpNadD crystals were cryo-cooled in 10 % ethylene glycol, frozen in liquid 
nitrogen and placed in a puck. All spNadD data were collected at the Advanced Photon 
Source at Argonne National Laboratory in Lemont, IL.  The diffraction experiments were 
conducted remotely on the 22ID beamline run by the Southeast Regional Collaborative 
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Access Team. All diffraction data was collected at 100 K, and results were processed using 
HKL-3000 (16).   
OTHER COMPUTATIONAL METHODS 
All other computational methods used are consistent with the methods used in 
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Figure 3.1: General reaction for spNadD: This figure is a schematic of the reaction 




Figure 3.2: The (T/H)XGH motif. Cartoon representation of a single Bacillus subtilis NadD 
chain. The magnified region depicts the position of the (T/H)XGH motif and its orientation 





Figure 3.3: Proposed structure of spNadD. Trimer structure from ecNadD (PDB code: 





Figure 3.4: Thermal stability results for uncut spNadD. This figure shows the results of 
average denaturation temperatures, for his-tagged spNadD, in various pH and salinity 





Figure 3.5: Thermal shift results for cut spNadD. This figure shows the results of average 
denaturation temperatures, for spNadD with a cleaved his-tag, in various pH and salinity 
conditions during thermal stability experiments. Each DSF experiment was done in 
triplicate.  




Figure 3.6: NadD small molecule stability. Thermal stability results of the top 20 stabilizers 

































Figure 3.7. NadD crystallization results. These are images of NadD crystals grown form 
0.1 M succinic acid, 15% w/v PEG 3350 (left), 20% w/v PEG 3350 (middle), and 20% w/v 






Figure 3.8: SpNadD sequence alignment. This figure shows the sequence alignment of 
spNadD and homologous proteins that have their structures deposited to the PDB. NadD 
homologs originate from the following organisms: Bacillus anthracis (baNadD), 
Mycobacterium tuberculosis (mtNadD), Staphylococcus aureus (saNadD), Bacillus 
subtilis (bsNadD) and Burkolderia thailandensis (btNadD).  The area highlighted in black 
box is the location of the highly conserve (T/H) XGH motif that is characteristic of proteins 





Figure 3.9: SpNadD homology model.  Cartoon representations of spNadD model based 
on Bacillus anthracis NadD structure (PDB code: 3E27). Areas highlighted in red (left) 





Figure 3.10: SpNadD homology models. Cartoon representations of various spNadD 
models. The model in green was generated using the baNadD structure (PDB code: 3E27) 
as a template; the orange model was generated using bsNadD structure (PDB code: 
1KAM), the gray model was generated using saNadD structure (PDB code: 2H29), and the 





Figure 3.11: SpNadD structural homolog active site comparisons. This figures show 
comparisons the of active site locations on single NadD chains for proteins originating 
from Staphylococcus aureus (saNadD-green), Bacillus anthracis (baNadD-cyan), 
Mycobacterium tuberculosis (mtNadD) and Bacillus subtilis (bsNadD). Each of the 
structures contain a NaAD molecule within the site, except for the bsNadD structure which 





Figure 3.12: SpNadD putative substrate binding pocket. Surface representations of 
mtNadD (left) and bsNadD (right) showing open and closed formations of the active site 
in the presence of NaAD. The area highlighted in the red is the location of the (T/H)XGH 
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STRUCTURAL AND FUNCTIONAL STUDIES OF STREPTOCOCCUS PYOGENES NH3-DEPENDENT 
NAD+ SYNTHETASE (SPNADE) 
4.1 INTRODUCTION 
SpNadE is the responsible for the formation of NAD+ by the catalyzing the last step 
of the QSP responsible for the conversion of NaAD and ATP into NAD+ (Figure 4.1) (1). 
This enzyme is relatively well studied, and proteins from Bacillus anthracis, Bacillus 
subtilis, and Escherichia coli are characterized functionally and structurally. (2, 3, 4). 
Proteins originating from Burkholderia pseudomallei, Deinococcus radiodurans, 
Pseudomonas aeruginosa, and Vibrio cholarae have their structures determined, but there 
are no publications describing these enzymes.  
SpNadE also belongs to the Adenosine Nucleotide -Hydrolase (AANH) 
Superfamily (6, 7, 8). Proteins in this superfamily have Rossman-like alpha/beta/alpha 
sandwich fold (InterPro code: IPR014729) and are characterized by the presence of a “PP-
loop” commonly found close to the N-terminus of the protein (8). In this loop a “SGGXD” 
motif is commonly found which is considered to be important for phosphate binding (8). 
Other proteins within this superfamily include: GMP synthases, tRNA methyl transferases, 
and arginosuccinate synthases (8).
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Previous studies have identified NadE homologs as dimeric proteins (2, 3, 4). The 
dimer has two binding sites for ATP and two binding sites for NaAD (2, 4).  The ATP 
binding site is contained within a single protein chain, while NaAD binding site 
corresponds to a lateral cleft stretching across both protein chains (2, 4). The formation of 
NAD+ is proposed to operate in an ordered-sequential fashion with binding of ATP 
occurring first, followed by the binding of NaAD for the initial formation of an NaAD-
adenylate intermediate (3, 4). The adenylate intermediate has been shown to be stabilized 
by interaction with two Mg2+ ions (4).  Upon formation of the intermediate species, it is 
presumed that a nucleophilic attack by the lone pair of free NH3 occurs at the C7 carbonyl 
carbon of the adenylate species (2). This attack results in the release of AMP and inorganic 
pyrophosphate (PPi) leaving NAD
+ to be reduced for eventual NADH formation (2). This 
incidence, by the action of NH3 only, has been identified in E. coli and B. subtilis.  
NAD+ synthetases in Mycobacterium tuberculosis (mtNadE), Saccharomyces 
cerevisiae (scNadE), and Homo sapiens (hsNadE) are glutamine dependent. Glutamine 
acts as a -NH3 donor to promote the same nucleophilic attack as described above and leaves 
NAD+, AMP, PPi, and glutamate as its end-products. (9). HsNadE and scNadE are 
considered to be exclusive to glutamine while mtNadE has been shown to be able to utilize 
both glutamine and NH3 (4, 9).  
Rodionova et al. identified that the nadE gene is essential for bacterial survival 
(10). In knockdown studies, using Mycobacterium smegmatis, they showed nadE (or 
nadD) silencing produced diminished growth of the bacterium in culture (10).  The 
Database for Essential Genes (DEGG) also showed that NadE, from GAS, contains 
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significant sequence alignment to essential, proteins produced in other pathogenic species 
(i.e. S. aureus and V. cholarae) (11).   
Therefore, NadE seems to be a promising new target for development of 
antibacterial compounds.  There is still very little information identified about this protein 
in GAS. This dissertation provides the first information the kinetic activity of the protein, 
as well as, the first structures of NadE originating from S. pyogenes.   
4.2 RESULTS AND DISCUSSION 
 PROTEIN PRODUCTION 
 Recombinant spNadE was successfully produced in high quantities. It was 
estimated that after the nickel-affinity chromatography there was, on average, 340 mg of 
spNadE, per 1 L culture. The last step of protein purification involved size-exclusion 
chromatography. As judged by the SDS-PAGE the protein purity was greater than 90%.  
The results from the size-exclusion step indicate the presence of one major peak 
corresponding to a spNadE dimer, when compared to commercial standards. These results 
were consistent with DSL results that indicate presence of an assembly in solution with 
molecular weight of 72 ±5.3 kDa.  The molecular weight of a spNadE with the purification 
tag is 34 kDa. Attempts to remove the purification tag, with TEV protease, were 
unsuccessful.  
NADE KINETIC DATA 
At increasing NaAD concentrations, spNadE shows Michealis-Menten kinetics. 
With spNadE at a 13 pmol concentration, results showed a  Km  of  375 µM. The kcat was 
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4.16 s-1  and the kcat/ Km was 11.09 s
-1 mM-1 (Table 4.1). At the sample protein 
concentration, with increasing ATP, spNadE showed a Km of  304 µM , a kcat of 5.63, and 
kcat/ Km of 16.55. At experiment concentrations of greater than 4 mM ATP, results showed 
ATP in excess caused an inhibitory effect. All experiments were conducted in triplicate, 
and these are the average values of each cuvette experiment. Kinetic results provide 
evidence to support that this protein is the most efficient of the QSEs. There is no other 
published data for spNadE kinetics and variability of results could be observed in 
experiments prepared in vitro. It also cannot be excluded that the presence of the 
purification tag may impact the enzymatic properties (12, 13).  As mentioned previously, 
the his-tag removal experiments were unsuccessful.  
Experimental results from protein homologs from Bacillus anthracis (baNadE) 
(58.5% sequence identity) indicate approximate Km values (Km(app))  for NaAD and ATP 
are 152 µM and 289 µM, respectively; the Bacillus subtilis (bsNadE) homolog (56.7 % 
sequence identity) reported a Km(app), for NaAD, at 179 µM and ATP at 196 µM (2, 14). 
No data was given for kcat/ Km (2, 14). In comparison to our experimental results our 
enzyme could be regarded to have a lower substrate affinity. Refer to Table 4.1 for a report 
of the kinetic results for spNadE compared to homologs from Bacillus anthracis and 
Bacillus subtilis. 
THERMAL STABILITY 
 DSF experiments performed in conditions with various pH and NaCl 
concentrations showed that the recombinant spNadE was more stable in low pH, high salt 
conditions (pH 4.0-4.5 and 500 mM NaCl) (Figure 4.2).  
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The results of the small molecules impact on protein stability indicate that the top 
stabilizing molecules, mellitic acid and 2-pyridine sulfonic acid, increase thermal stability 
of spNadE by 10 ° C as compared to the control (melting at 50 °C). Phenyl-2-thiourea and 
tetraamine copper (II) sulfate stabilized spNadE up to 58 °C. Co-crystallization 
experiments are currently being conducted to structurally confirm the binding of these 
molecules.  
CRYSTAL SCREENING AND OPTIMIZATION 
Crystals were obtained from Crystal Screen 1 (Hampton Research, Viejo CA) 
optimization experiments in the following condition: 0.1 M Tris (pH 8.5), 20% w/v PEG 
4000, and 0.2 M magnesium chloride. In hanging and sitting drop preparations small, 
needle-like clusters of crystals were obtained within 24 hours. While, these crystals were 
not suitable for diffraction, it was later found that underneath the needle clusters, within 
the same condition, were thin, rectangular, plate-like crystals (Figure 4.3). These crystals 
diffracted well, yet appeared inconsistently. The data obtained from the plate-shaped 
crystals allowed for the determination of the spNadE crystal structure to 2.5 Å and 2.1 Å.  
Significant effort was placed into optimization of crystallization conditions. The 
optimization attempts included crystallization in various temperatures, reductive 
methylation of the protein (for details see Chapter 3, page 63), and use of various additives. 
The additives used in these experiments could be divided into three groups. The first group 
included spNadE substrates, products or their analogs. The second group contained 
compounds, i.e. glycerol, that were introduced in order to slow-down the rate of 
crystallization, and the third group included compounds that were increasing protein 
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stability. Despite the fact, that thousands of crystallization experiments were performed no 
significant improvement of the crystallization conditions was obtained. 
ANALYSIS OF THE SPNADE SEQUENCE 
Genomic analysis indicate that the reading frames for the QSEs are dispersed within 
the genome, and are not expressed from the same operon (5). In other pathogenic bacteria 
(i. e. Staphlyococcus aureus and Helicobacter pylori) the nadE reading frame was, also, 
not found to be included on an operon with genes encoding for homologous QSP proteins. 
(5). In GAS, when compared to the other QSEs, the nadE reading frame is located the 
farthest downstream, from the origin, at position 1288286 to position 1289110. (5). 
The spNadE sequence contains 283 amino residues per protein chain (566 total in 
the dimer). An NCBI Protein BLAST search against sequences of proteins, with structures 
deposited to the PDB, revealed the presence of five major protein segments: the active site, 
the ATP binding site, the NAD+ binding site, the dimer interface, and the Mg2+ binding 
site(s) (Figure 4.4) (16). In accordance with BLAST results, the ATP binding site is 
considered to be composed of residues: 53-61 (LGISGGQDS; amino acids marked in bold 
are highly conserved), 88-91, 150, 168, 197, and 217-219. The NAD+ binding site is 
composed of residues: 53-56, 60-61, 89-91, 140, 144, 147-148, 150, 169, 174, 178-181, 
184, 219-220, 222, 234. The residues of the dimer interface include residues: 33-34,  37, 
39-41, 114-116,119-120, 123-124, 141, 145, 148-149, 151-153, 155-157, 159-160, 181-
182, 185-190, 193-194, 268-270. Magnesium binding residues include residues: 56, 60, 
174 and 218.  Areas of highest sequence conservation are between residues 53-61 and 143-
246.  In NadE from GAS, there is a “SGGQD” motif, which corresponds to residues 56-
85 
 
60. It should be noted that BLAST results do show residue overlap between segments. 
Substrate-bound spNadE structures will need to be determined to confirm this overlap. 
Sequence alignment studies comparing spNadE and hsNadE, using Clustal Omega 
(15, 16), reveal that the identity between these sequences is approximately 24% (Figure 
4.5). The low similarity between these proteins gives confidence that spNadE would be an 
optimal template for structure-based drug design. 
STRUCTURAL ANALYSIS OF SPNADE 
OVERALL STRUCTURE 
The NadE structure bound to Mg2+ and SO4
2- ions (spNadEsulf) was the first of the 
NadE structures to be determined (Figure 4.6). The protein crystallized in primitive 
orthorhombic system and P212121 space group with two protein chains in the asymmetric 
unit.  The structure was determined at 2.5 Å resolution. An NadE homolog from Salmonella 
typhimurium (PDB code: 3HMQ) was successfully used as the starting model for molecular 
replacement. The structure of spNadEsulf was refined to 0.171 Rcryst and 0.225 Rfree. The 
model of the structure includes a dimer and the protein chains include residues 9-214 and 
229- 282. Residues 215-228 from the highly conserved active site loop, are missing in both 
structures, which indicates that they are disordered in the absence of substrates. Similarly, 
the polyhistidine tags were also not modeled, as there is no visible electron density that 
corresponds to this fragment of the molecule. It is assumed that high entropy of the segment 
was the cause of in ability to visualize the electron density through x-ray 




The NadEsulf structure was used as a starting model during determination of the 
NadE apo structure (NadE-apo). The NadE-apo structure was determined at 2.1 Å 
resolution, and the final model was refined to Rcryst value of 0.168 and an Rfree of 0.212 
(Figure 4.7). The model included residues 9-96, 98-215, 228- 282 for each of the protein 
chain forming the dimer present on the asymmetric unit. The model of NadE-apo was 
deposited to the PDB with accession code 5HUJ. 
The single chain of spNadE has primarily alpha helical character with 11 alpha 
helices (68 % of secondary structure), 3 parallel beta strands (18%), and 2, 310 helices (13 
%) (Figure 4.8, Figure 4.9). The sequence and structure based searchers revealed that there 
are several spNadE homologs that have their structure experimentally determined.  
Homologous NAD+ synthetases that had the highest sequence identity originated from 
Salmonella typhimurium (PDB code: 3HMQ, 68 % sequence identity; stNadE), 
Escherichia coli (PDB code: 1WXI, 65% sequence identity; ecNadE), Bacillus anthracis 
(PDB code: 2PZA; 58% sequence identity; baNadE) and Bacillus subtilis (PDB code: 
2NSY; 57% sequence identity; bsNadE) (18). Structure of these proteins were used to 
identify putative substrate binding sites for spNadE, and gave the following RMSD values, 
using Coot SSM superpose: 0.69 Å (over 251 Catoms) for stNadE; 0.62 Å (over 257 C 
atoms) for ecNadE, 0.74 Å (over 254 C atoms) for baNadE,  and 0.85 Å (over 254 C 
atoms) for bsNadE. Figure 4.10 highlights the regions of the spNadE structure that are the 






Gel-filtration and DSL results indicated that spNadE forms dimers in solution. 
These results are in agreement with structural analyses that show the presence of a dimeric 
assembly in the asymmetric unit. We assume that the dimer observed in the crystal 
corresponds to the biological assembly of spNadE. According to PDBpisa calculations 
(19.), the dimer interface for spNadE-apo covers 2407 Å2 and the same interface for 
spNadEsulf covers 2407 Å
2.  
ACTIVE SITE  
Sequence homology analysis, using NCBI Protein BLAST, in combination with 
structural studies, indicate that there are approximately 18 residues responsible for the 
architecture of the active site. Through analysis of the structure it was evident that there 
was no electron density for 15 of the residues due to possibly high entropy in that region. 
Through sequence homology studies of this region, specifically residues 215-223, it was 
determined that these residues were highly conserved and make up a loop structure within 
that region. Using a structural homolog from bsNADE (PDB code: 1EE1) we modeled the 
loop into this region in order to obtain some impression of the activity of this loop within 
this region (Figure 4.11). It should be noted that bsNadE (PDB code: 1EE1) structure was 
one of the few structures that determined the orientation for the loop structure (20). This 
loop has also been indicated in the stabilization of Mg2+ within the ATP binding site, as the 
ATP binding site shares 3 residues with this site. The architecture of this site will be 
discussed in greater detail in the next section.  The residues for the loop of interest include 
E215, K216, V217, P218, T219, A220, D221, L222, E223 from spNadE. In bsNadE 
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residues include:  L222, K223, E224, P225, T226, A227, D228, L229, and L230. Both 
loops are have approximately 67% sequence identity.  
SPNADE ATP/ Mg2+ BINDING 
 ATP and Mg2+ binding sites in NadE were shown to be composed of residues from 
a single protein chain.  Sequence homology studies of structural homologs of the spNadE 
provide evidence to support that binding of the ATP occurs solely within the individual 
chains of the dimeric assembly and not at the interface.  Residues involved in the conserved 
“SGGXD” motif, described above, are also is found at this site.  
 Sequence homology studies of spNadE identifies residues: L53, G54, I55, S56, 
D60, S61, V89, R90, L91, R150, T168, K197, V217, P218, and T219 to be responsible for 
the providing a binding pocket for ATP. Residues P218 and T219 (as well as any other 
residues between 216-227) are not visible in the electron density due to a conformational 
flexibility in that region. To describe the architecture of this site, I used structures from 
ecNadE (PDB code: 1WXI) (Figure 4.12, 4.13) and bsNadE (PDB code: 1EE1) (Figure 
4.14).  
Sequence homology results also show that the residues responsible for Mg2+ 
binding are the most highly conserved (100% sequence identity) between the structural 
homologs. BLAST results for spNadE show Mg2+ binding residues include: S56, D60, 
E173, and T218 (T218 was not visible, as described above) (Figure 4.15, 4.16). (18).  
The ATP binding sites between the spNadE-apo and ecNadE AMP-bound structure 
(PDB code: 1WXI) do not show any significant cavity differences. When the bsNadE (PDB 
code: 1EE1) was superposed on the structure it provided evidence that the conserved loop 
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region closes off the ATP binding site and could play a role in the prevention of new ATP 
molecules entering into the site (Figure 4.17). We assume that when NAD+ is released, the 
site re-opens and allows for access of another ATP molecule.  
NAAD BINDING SITE 
According to previous studies on similar -NH3 dependent NadE homologs, NaAD 
has been shown to bind across the dimeric chains in a cleft that is below the ATP binding 
site (Figure 4.18) (20). This binding event should allow for the interaction of the -
phosphate of ATP with the carboxyl group of the pyridine ring of NaAD in order to allow 
for the formation of the NaAD-adenylate intermediate. According to sequence homology, 
residues responsible for the formation and stabilization of NaAD binding site in spNadE 
include: L53- S56, D60, S61, V89-L91, F140, G143, N144, A147, R148, R150, T168, 
E173, F178-K181, D184, T219, A220, L222,  and A234 (Figure 4.19) (18). SpNadE 
residues T219, A220, and L222 are not visible in the electron density. When compared to 
bsNadE, NaAD binding site residues have approximately 85% residue identity. 
In the surface representation comparisons between apo spNadE and, NaAD-bound, 
bsNadE it was identified that the substrate binding pocket, for bsNadE, was visually, larger 
than the predicted NaAD binding site for spNadE. Using Coot and PyMOL, we superposed 
the structures and measured the distance between two residues that were directly across 
from each other, on opposite sides of the binding pocket. These measurements were taken 
across the centermost point of the pocket in an attempt to confirm an actual size difference. 
More specifically, we, first, measured the distance between the  carbon of F128 and the  
sulfur of M253 of bsNadE. Then, we measured the distance between the   carbon of F139 
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and  carbon K264 of spNadE. Results from these residue measurements identified that the 
distance between F128 to M253 in (bsNadE) was 1.8 Å wider than the distance between 
F139 and K264 (spNadE) (Figure 4.20). It was concluded that NaAD binding site is larger 
when the substrate is bound. 
Moreover, further analysis of the area shows that NaAD binding site expansion 
seems to occur as an effect of the closure of the ATP binding site, after ATP is bound. This 
occurrence is presumed to be similar to how the compression one end of a balloon causes 
expansion of the opposite end.  In contrast, ATP site expansion was identified when NaAD 
is unbound. When NaAD is not bound, the structure reveals an open conformation of the 
ATP binding site is and a more narrow conformation NaAD site, as described above 
(Figure 4.21).  This observation lead us to believe that the general mechanism for NAD+ 
biosynthesis is an ordered-sequential reaction (21) (Figure 4.22). We believe that the ATP 
binding event occurs first, then the loop structure of the active site clamps down, which 
promotes the open conformation of the NaAD site for acceptance of the substrate (Figure 
4.21). More kinetic and structural studies will need to be done to confirm this occurrence. 
NH3 CHANNEL 
NAD+ biosynthesis can also occur through the utilization of glutamine as an -NH3 
donor, for nucleophilic attack, to convert the NaAD-adenylate intermediate into NAD+. 
This mechanism is most common in Mycobacterium tuberculosis (M. tuberculosis), Homo 
sapiens, and Saccharomyces cerevisiae (4).  MtNadE has been identified to have the ability 
to utilize -NH3 and glutamine to make NAD
+ (4, 22). 
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The mtNadE (PDB code: 3SYT) structure is a large (600 kDa) octomeric biological 
assembly structure with general characteristics similar to a cross, with a hollow, center 
cavity (9). At the apex of each corner of the cross resides the C-terminal NAD+ synthetase 
domain (9). This domain is a structural homolog of spNadE (RMSD of 1.6 Å) (Figure 
4.23). Beneath the synthease resides glutaminase, an N-terminal amidotransferase, region 
that that promotes the loss of –NH3 necessary for the NAD
+ synthetase reaction (Figure 
4.24) (9).  From work conducted by LaRonde-LeBlanc et al., it was identified that 
glutamine enters through a “tunnel system” in which ends at a Glu-Lys-Cys triad that is 
proposed to promote the loss of -NH3 from the  carbon of glutamine (Figure 4.25) (9). 
Once -NH3 is released it passes into a second “tunnel system” to initiate the nucleophilic 
attack on the NaAD adenylate intermediate, as described previously.  The entire occurrence 
is proposed to travel approximately 73 Å before the reaction is complete (Figure 4.26, 
4.27). Kcat for this reaction was 0.68 and Kcat/Km was defined at 0.4 s
-1 mM-1 (9).    
Structural homology studies have lead us to conclude that the direction of 
nucleophilic attack comes from underneath the spNadE structure through channels formed 
at the interface of the A and B chains (Figure 4.28). The residues that make up this interface 
are made up of loop structures and include: Q18, L19, G167, T168, D169, N174, F179, 
T180, K181, F182, G183, D184, G185, G186, A187, D188, F193, R270, H271, L272, 
P273, and I274. This area is not highly conserved, and contains few hydrophobic residues. 
This observation could provide reasoning for ease of access to shared NAD+ binding site 
residues within this region. We infer, from this result, that passage of -NH3 in spNadE will 
occur at the same entrance point that the tunnel system affords for mtNadE synthetase 
region. Further tests will need to be conducted to confirm this assumption. 
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4.3 MATERIALS AND METHODS 
PROTEIN PRODUCTION AND CRYSTALLIZATION: 
The methods used for protein production and crystallization were the same as those 
described in Chapter 2, pages 27-30. 
DYNAMIC LIGHT SCATTERING:   
The methods used for Dynamic Light Scattering are outlined in Chapter 2, page 30. 
THERMAL STABILITY TESTS: 
   The methods used for Thermal Stability test are outlined in Chapter 2, page 30-31.  
Small molecule stability screening tests were done utilizing the strategy outlined in Chapter 
3, page 64.  
NADE KINETIC ASSAY 
NadE activity was conducted at 1 mL, using a quartz cuvette.  Activity reaction 
solution concentrations are as follows: 60 mM HEPES (pH 7.5), 2 mM NaAD, 2 mM ATP, 
10 mM ammonium chloride, 10 mM MgCl2, and 20 mM KCl, 0.5 µg of NadE, 1% ethanol  
and 1 µg of alcohol dehydrogenase (ADH; Sigma-Aldrich St. Louis, MO) (protocol was 
adapted from Nessi et al.) (11). ADH was necessary to confirm NAD+ formation through 
its ability to promote a hydride shift to form NADH. NADH formation was detected by 
UV at 340 nm. Reactions were measured at 340 nm for 5 minutes. Kinetic experiments 
were prepared with increasing amounts of one substrate while keeping the other substrate 
at activity reaction concentrations. ATP kinetic experiments concentrations are as follows: 
0.5 mM, 1 mM, 2 mM, 4 mM, 6 mM, 8 mM, 10 mM, and 12 mM. NaAD kinetic experiment 
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concentrations are as follows: 0.125 mM, 0.250 mM, 0.500 mM, 1 mM, 1.5 µM, 2 mM, 
and 2.5 mM. Reactions were conducted using the Nanodrop 2000c UV spectrometer. 
DATA COLLECTION AND DATA PROCESSING 
  Prior to data collection NadEsulf crystal was transferred to the solution of cryo-
protectant composed of 10 % glycerol, 5% w/v PEG 3350, and 0.1 M ammonium sulfate. 
The NadE-apo crystal was cryo-cooled by direct transfer from the drop to liquid nitrogen.  
Diffraction data were collected at the Advanced Photon Source at Argonne National 
Laboratory in Lemont, IL. The data from NadE-apo crystal was collected at 19 ID of the 
Structural Biology Center Collaborative Access Team (SBC-CAT) and data from the 
NadEsulf crystal was collected at 21 ID-G at the Life Sciences Collaborative Access Team 
(LS-CAT).  Diffraction experiments were performed at 100 K. Data processing was 
performed with HKL-2000 and the details on the diffraction experiments and collection 
statistics are summarized in Table 4.2. 
STRUCTURE DETERMINATION, REFINEMENT AND VALIDATION 
HKL-3000 in combination with MOLREP were used for structure determination. 
Both of the NadE structures were solved by molecular replacement. The structure of 
NadEsulf was solved first using as the starting model the NAD
+ synthetase Salmonella 
typhimurium (PDB code: 3HMQ; 67% of sequence identity).  The structure of NadEsulf was 
used as a starting model for determination of NadE-apo structure. Both structures were 
refined with HKL-3000 and Refmac. Coot was used for model building and adjustment, as 
well as for structure validation. The final validation was performed with Molprobity and 
CheckMyMetal. Both structures together with structure factors were deposited to the 
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Protein Data Bank under the accession codes 5HUJ and 5HUH for NadE-apo and NadEsulf, 
respectively. Information on model refinement and validation was summarized in Table 
4.3. 
OTHER COMPUTATIONAL METHODS 
 The other computational methods used are the same as were described in Chapter 




4.4 TABLES AND FIGURES 
Table 4.1: Kinetic results from spNadE experiments. These results are compared to results 









spNadE NaAD ATP 375 ± 0.12 4.16  11.09 
 ATP NaAD 340 ± 0.03 5.63  16.55 
bsNadE NaAD ATP 152  NR NR 
 ATP NaAD 289  NR NR 
baNadE NaAD ATP 179  NR NR 





Table 4.2: Summary of NadE and NadEsulf data collection and processing. 
Protein NadEsulf NadE-apo 
PDB accession code 5HUH 5HUJ 
Diffraction source APS (21 ID) APS (19 ID) 
Wavelength (Å) 1.000 0.979 
Detector MX300HS ADSC Q315r 
Crystal-to-detector distance (mm) 300 300 
Rotation range per image (°) 1 1 
Total rotation range (°) 200 200 
Exposure time per image (s) 1 1 
Space group P 21 21 21                P 21 21 21                
a, b, c (Å) 49.521 92.104  
128.569  
49.786   92.964  
128.355  
Resolution range (Å) 50.00- 2.50 (2.54- 
2.50) 
39.37- 2.10 (2.14- 
2.10) 
σ Cutoff -3  -3  
Total No. of reflections 19874 (856) 32708 (1586) 
Completeness (%) 92.6 (82.9) 91.8 (90.5) 
Redundancy 6.6 (5.3) 5.6 (5.0) 
〈 I/σ(I)〉  7.5 (2.4) 
 
11.9 (2.3) 
 Rr.i.m. 0.159 (0.588) 0.156 (0.862) 
Rp.i.m. 0.060 (0.238) 0.064 (0.373) 
Overall B factor from Wilson plot 
(Å2) 
26.8 29.6 




Table 4.3. Summary of spNadE and spNadEsulf structure refinement statistics 
Protein NadEsulf NadE-apo 
Resolution range (Å) 43.72-2.50 (2.56-2.50) 39.37- 2.10 (2.15-2.10) 
Completeness (%) 93.10 (92.1) 91.66 (89.5) 
 Cut-off 0 0 





No. of reflections, test set 1338 1630 
Final Rcryst 0.171 (0.222) 0.168 (0.205) 
Final Rfree 0.225 (0.279) 0.212 (0.282) 
No. of non-H atoms 4301 4291 
Protein 4025 4025 
Ligand 27 1 
Solvent 249 265 
R.m.s deviations   
Bonds (Å) 0.012 0.016 
Angles (°) 1.4 1.6 
Average B factors (Å2)   
Protein 32 29 
Ligand 74 38 
Ramachandran plot   
Most favored (%) 98.8 99.2 
Allowed (%) 99.8 99.6 
Visible Residues   
Chain A 9-215, 228- 282 9-97, 99-215, 228- 282 





Figure 4.1: Schematic of general spNadE reaction. This diagram shows the general 





Figure 4.2: SpNadE DSF result. Chart depicts differential scanning fluorimetry results for 





Figure 4.3: SpNadE crystallization results.  The image on the left shows a picture of the 
needle-like cluster of spNadE crystals. The right image shows the rectangular, plate-like 






Figure 4.4: SpNadE sequence alignment. This image show  sequence alignment results for 
spNadE and its homologs originating from Salmonella typhimurium (stNadE), Eschericia 
coli (ecNadE), Bacillus anthracis (baNadE), Vibrio choloera (vcNadE), Pseudomonas 
aeruginosa (paNadE), Bortadella pertussis (btNadE), Fracisella tulerensis (ftNadD), 





Figure 4.5: Sequence alignment of spNadE and hsNadE. This alignment result shows low 
sequence identity and similiarity between the bacterial and human protein.  The sequence 





Figure 4.6: Cartoon representation of spNadEsulf. This is a cartoon representation of 
spNadEsulf in various orientations bound to sulfate and Mg





Figure 4.7: Cartoon representation of apo spNadE. This is a cartoon representation of the 






Figure 4.8: The spNadE monomer. Cartoon representation of spNadE monomer at various 
orientations. Alpha helices are colored in cyan, beta-strands are colored red, and loop 





Figure 4.9:  SpNadE monomer with marked missing residues. Cartoon representation of 
spNadE monomer shown at two different orientations. Missing residues on this structure 
include residues 97 and 216-227. The missing region from E215-L228 is highlighted in red 
to indicate that this region is highly conserved and will be described in greater detail in 
later figures. Alpha helices are colored in cyan, beta-strands are colored red, and loop 






Figure 4.10: Cartoon representation of conserved regions of spNadE. Cartoon and surface 
representations of the spNadE dimer in various orientations. The dark blue color shows 





Figure 4.11:  SpNadE and proposed active site. Cartoon representation of spNadE with 





Figure 4.12: Proposed spNadE ATP binding site. Cartoon representation of spNadE 
superposed with ecNadE (salmon) (PDB code: 1WXI) to show probable location of ATP 





Figure 4.13: Proposed ATP binding pocket. Cartoon representation of spNadE and ecNadE 
(salmon) (PDB code: 1WXI) to show probable location of ATP binding site without the 
conserved loop. AMP is bound to ecNadE and the green spheres are two Mg2+ molecules. 
The AMP molecule bound in lower right quadrant of the ecNadE molecule may give 





Figure 4.14: SpNadE modeled with active site loop. Surface representation of spNadE with 
a superposed loop from bsNadE. Areas highlighted in red represent conserved regions for 
the ATP and NaAD binding sites. Images to the far right are meant to display conserved 
residues of the loop that interact with the site without (top) and with (bottom) substrate.  






Figure 4.15: Highly conserved spNadE Mg2+ binding site. The superposition of Mg2+ 





Figure 4.16: Conserved Mg2+ binding site superposed with equivalent fragment of ecNadE. 
The superposition of Mg2+ binding site residues for spNadE apo structure (yellow) and 





Figure 4.17: Surface representation of ATP binding site with and without the active site 
loop. The image to the left (yellow) is spNadE, the middle image (salmon) is ecNadE (PDB 
code: 1WXI), the right figure is the bsNadE (PDB code: 1EE1). For the bsNadE figure the 
area highlighted in red represents the conserved loop region that, essentially, closes off the 





Figure 4.18: Proposed spNadE NaAD binding site. Cartoon and surface representation of 
proposed the spNadE NaAD binding site of NaAD from superposed bsNadE structure 





Figure 4.19: Proposed spNadE residues for NadE binding. Cartoon representation of 






Figure 4.20: SpNadE NaAD binding site size comparison. The comparison of spNadE 
(yellow) and bsNadE (green) (PDB code: 2NSY: RMSD 0.85 Å) NaAD binding site 
residues. Distances are measured from the  carbon of F128 to the  sulfur of M253 
(bsNadE) and the   carbon of F139 to the  carbon of K264. Structure comparisons 







Figure 4.21: SpNadE ATP active site comparison. Cartoon representation spNadE and 
bsNadE (cyan) (PDB code: 2NSY) with boxes showing how open the ATP binding site is 
when no substrate is bound. This observation lead to the assumption that ATP binds first 







Figure 4.22: Cleland diagram of proposed general mechanism for spNadE. Schematic of a 






Figure 4.23: Comparison of spNade and mtNadE. Cartoon representation of the octameric, 
glutamine-dependent NAD+ synthetase from M. tuberculosis (PDB code: 3SYT). On the 
left SpNadE (yellow) has been superposed on this structure to show its similarity to the 
NH3 synthetase region of mtNadE. On the right, spNadE is colored by chain and this color 





Figure 4.24: The glutamine and NH3 channel for mtNadE.  Surface representation showing 
superposition of of mtNadE (PDB code: 3SYT, grey) and spNadE (yellow and blue). This 
image provides a generalized diagram of the direction of the “tunnel system”. The system 
is composed of two tunnels: the first binds Gln at the Glutaminase/ amidotransferase region 
and promotes the removal of NH3, the second transfers NH3 to the synthetase region for 






Figure 4.25: Schematic of the the NH3 tunnel of mtNadE.  The diagram adapted from 
LeRonde-LeBlanc et al. shows a general mechanism for NAD+ biosynthesis in glutamine-





Figure 4.26:  The proposed NaAD binding site in the mtNadE synthetase domain. SpNadE 
(yellow and blue) is superposed on mtNadE (PDB code: 3SYT; grey). NaAD is shown in 






Figure 4.27: The discovery of the possible direction of NH3 entrance in spNadE. Surface 
representation of spNadE superposed on mtNadE (PDB code: 3SYT) to show the proposed 
direction of travel of NH3 from the glutaminase/ amidotransferase region to the NAD
+ 
synthetase region. The yellow/blue structure to the far right removes the superposed 
mtNadE structure to show evidence of two openings at the dimer interface of NadE that 
may provide insight into the direction of nucleophilic attack on the NaAD-adenylate 





Figure 4.28: The proposed NH3 passageway. Cartoon (left) and surface representations 
(right) of spNadE and NaAD molecules superposed from mtNadE (PDB code: 3SYT). The 
NaAD substrates are located behind the NH3 passageway (highlighted in pink).  Cavities, 
indicated by the circles, could explain the direction of nucleophilic attack of NH3. We 
presume that NH3 enters through one of these cavities in order to promote the conversion 
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THE STRUCTURAL CHARACTERIZATION OF SAGB, SAGC, SAGD AND SAGG PROTEINS 
FROM STREPTOCOCCUS PYOGENES 
5.1 INTRODUCTION 
In GAS the proposed SagBCD complex, composed of proteins expressed from the 
sag operon: SagB, SagC, and SagD, is considered to be primarily responsible for the 
biosynthesis of SLS (1, 2). More specifically, as suggested by Molloy et al., the expression 
of the sagA reading frame, of the sag operon, results in the translation of a 53 amino acid 
strand (SagA). The strand is then converted into Streptolysin S (SLS) by the activity of the 
SagBCD. As determined through sequence homology studies, the SagA strand is divided 
into two segments: the leader peptide segment (residues M1-G23) and the protoxin 
segment (residues C24-T53). The leader segment contains an FXXXB motif (F4-I8: 
FTSNI) that is considered to be a recognition sequence for truncation of the strand by SagE 
(1, 3) (Figure 5.1). The mechanism for this truncation event has yet to be confirmed, but is 
presumed to be one of two events that is necessary in the conversion of SagA into SLS (1, 
2). The second event involves the modification of cysteine, serine, and threonine residues 
within the protoxin segment (2). The chemical mechanism for this event is also undefined. 
The protoxin sequence (…↓CCCCCTTCCFSIATGSGNSQGGSGSYT) is considered to 
continue thru biosynthetic modification by action of SagBCD (Figure 5.2). Within the 
complex, SagC, a cyclodehydratase, is considered to act first in the conversion of the
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 cysteine, serine, and threonine residues into thiozole, oxazole, and metyloxazole rings, 
respectively (2). SagB is a proposed dehydrogenase, using flavin mononucleotide (FMN) 
as a cofactor, and is responsible for double-bond formation, within the rings (Figure 5.2). 
This step is considered the “finishing step” in the conversion of SagA into SLS. SagD is 
considered to be the docking protein that keeps the complex together to allow for SLS 
biosynthesis (1, 2) Sequence homology studies have identified the possibility of ATP being 
required for the activity of SagD (4). This interaction has yet to be confirmed. 
Research interests also lie in the determination of the structure and function of 
SagG. SagG is a membrane associated protein proposed to play a role in the formation of 
the, membrane-bound, ATP-binding cassette. This cassette is considered responsible for 
the release of SLS into the extracellular environment (1, 2).  
Currently the Protein Data Bank (PDB) contains no other structures with significant 
sequence similarity (over the entire sequence) to SagB, SagC, SagD, or SagG (Refer to 
Chapter 1, Table 1.2)   
This chapter will provide a description of production of SagB, SagC, SagD and 
SagG proteins, as well as approaches used in an attempt to obtain their crystals.   
5.2 RESULTS AND DISCUSSION 
PROTEIN PRODUCTION 
SagB-D plasmid construction, protein expression, and purification protocols were 
the same as described for QSEs (Chapter 2, pages 27-30).  In contrast to QSE isolation 
results, isolation attempts produced only microgram quantities of soluble protein, per liter 
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of culture (Figures 5.3- 5.5). SagD gel filtration results provided evidence of possible dimer 
formation, when compared to peaks from protein standards (results not shown). With the 
assistance of an undergraduate volunteer, David Mysona, we were able to isolate, at least, 
5 mg of SagG per liter for culture (Figure 5.6). Additionally, SagG was found to be unstable 
in the imidazole-containing elution buffers, so immediate dialysis was required upon 
elution. Attempts to modify the growth conditions by changing IPTG concentrations, 
growing cultures in minimal media, decreasing inoculation temperature, and over-
expression of the protein in different cell lines were used in attempts to improve folding 
and stability. None of the attempts were successful at improving protein yield in any of the 
Sag proteins.  
Attempts were also made to isolate homologous proteins from different bacteria 
and different GAS strains. Work was initiated for the overexpression of the bacteriocin 
biosynthesis cyclodehydratase protein from Staphylococcus aureus in BL21 (DE3) E. coli. 
This protein is a structural homolog of SagC is predicted to be a more stable protein 
construct for crystallization (5). To date, attempts to isolate this protein have been 
unsuccessful.  
A SagD analog was, also, identified from the M6 strain from GAS from the 
DNASU plasmid repository (Tempe, AZ). This construct is referred to as 
“SagD_DNASU”.  The plasmid is designed to express for Kanamycin-resistance and a 6x, 
C-terminal, polyhisitidine tag. There is a variation in molecular weight between SagD, at 
51 kDa, and SagD_DNASU, at 45 kDa. More specifically this difference is due to a 50 
amino acid truncation at the N-terminus of the sequence and a 48 residue extension at the 
C-terminus (residues 346-394) of SagD_DNASU. In addition, the protein from DNASU 
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carries a tyrosine mutation at residue 124 (Figure 5.6). Isolation attempts produced 
approximately 24 mg of protein per liter of culture, (after dialysis). Unfortunately, as 
determined from gel filtration results, a large percentage (~90%) of the isolated product 
was considered aggregate protein. A non-aggregated fraction (not shown) that was 
confirmed to contain SagD_DNASU and was screened for crystal formation, but no 
crystals have been obtained to date. 
Refolding attempts on all of the Sag proteins were conducted and provided 
marginal success. The refolding conditions were partially based on Thermo Scientific 
Pierce® Protein Refolding Kit, and the conditions are listed in Table 5.1 (14).  The most 
optimal conditions for refolding, for SagB, were solutions 2 and 3. For SagC, no 
precipitation was observed in solution 9, and for SagD solutions: 1, 2, 3, 4, 6, 8, 14, 15 
were most optimal for refolding. Unfortunately, when gel filtration/ size exclusion 
chromatography was conducted, the peaks were presumed to be evidence of non-specific 
aggregation. 
SagG was most stable in refolding condition 12. After the elution from the Ni-NTA 
column the protein was approximately 85-90% pure.  As a result, the protein was further 
purified using gel filtration. The refolding of SagG proved to be only moderately successful 
as we were able to isolated only ~1 mg of pure protein from an, initial, 1L culture. 
CRYSTALLIZATION 
Due to protein aggregation and low protein yields only, approximately, 1000 
combined crystal screening experiments were conducted for SagB-G.  
MOLECULAR CLONING OF SAGBCD 
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The marginally successful attempts at SagB, SagC and SagD isolation prompted us 
to develop a methodology for expression of the entire SagBCD complex. Our approach 
was based on the strategy presented by Markley et al. (2012) (6). For the co-expression of 
the Sag proteins we enacted two slightly different approaches.  Results for Strategy 1, 
SagBCD co-expression using two plasmids, showed that SagB was successfully introduced 
into the pETDuet™ (Novagen, Madison, WI) plasmid and it has been confirmed through 
sequencing (Figure 5.8). There were numerous attempts, to insert SagD into the second 
multi-cloning site, in the plasmid, but attempts have been unsuccessful. However there was 
success with the addition of new restriction sites to the SagD insert (Figure 5.9).  Results 
for Strategy 2, SagBCD expression from 3 individual plasmids, showed some success as 
evidenced by growth of transformed BL21 (DE3) E. coli on the 
Ampicillin/Kanamycin/Chloramphenicol infused LB agarose plates. The introduction of 
each of the individual plasmids still needs to be confirmed through sequencing (refer to 
Figure 5.10 for agarose gel results). Culture and over-expression of the proteins showed 
evidence of protein production (not shown) although the product was completely insoluble. 
HOMOLOGY MODELING  
We used PHYRE2 for homology modeling and the approach described in the 
homology modeling section in Chapter 3, page 60. Collectively, structure confidence 
parameters for top homology models was greater than ≥99 %, but sequence identity for 
models ranged from 10- 41%. The homology models, with quality parameters of 100% 
confidence, included templates from: Thermotoga maritima (PDB code: 4EO3; sequence 
identity: 18%; 69% sequence coverage) for SagB,(Figure 5.11), Escherichia coli (PDB 
code: 3H9G; sequence identity: 10%; 91% sequence coverage) for SagC (Figure 5.12 ), 
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Prochloron sp. 06037A (PDB code: 4BS9; sequence identity 23%; 79% sequence 
coverage) for SagD (Figure 5.13), and Thermotoga maritima  (PDB code: 4YER; sequence 
identity 41%; 74% sequence coverage) for SagG (Figure 5.14). The results of the homology 
modeling suggest that SagG, SagB, SagC and SagD proteins most likely dimerize. 
Therefore, one may speculate that the enzymatic complex responsible for SLS formation 
has composition (SagB)2(SagC)2(SagD)2 and not SagBCD as reported in the literature.   
FUTURE DIRECTIONS 
In order to increase the likelihood of Sag protein isolation and overcome issues with 
solubility new strategies must continue to be initiated.  New approaches include: 
introducing substrates (i.e. ATP and/or SagA) into the culture media during growth and 
over-expression. The assumption is that through substrate interaction the proteins can be 
stabilized and could allow for higher yields of soluble during isolation. SagD was identified 
to be a similar to proteins that are a part of the YcaO family of proteins which are 
considered responsible for the formation of thiazole and oxazole modifications in bacteria; 
they are proposed to require ATP for activity (4, 7).  
To improve protein yield utilizing conditions that can slow the rate of protein over-
expression could be conducive to improving solubility. Possible avenues of approach could 
be the growth of the transformed bacteria in minimal media and/or the use of Arctic 
Express Cells (Agilent Technologies, Santa Clara, CA) which contain chaperones proteins 
that can allow for folding at temperaturs ranging between 10- 13 °C.   
Another strategy involves protein engineering and the addition of maltose-binding 
protein (MBP) to the N or C-terminus of each of the Sag proteins. Maltose binding proteins 
has been shown to improve solubility of unstable proteins, when attached (8).  Deletions 
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of predicted unstructured fragments and/ or a change of the His-tag location may also be 
useful approaches. (9, 10, 11) 
While the expression of all three of the proposed SagBCD complex proteins have 
been completed, in one cell, continued work will need to be done to improve yield of the 
complex proteins in order to visualize interactions, if any, through x-ray crystallography. 
Continued work will also be done to attempt to introduce SagD into the pET-Duet plasmid 
that contains SagB. Introduction of new restriction sites have been completed for SagD 
(Figure 5.7), but a more optimized strategy for ligation needs to be prepared to successfully 
insert the SagD into pET-Duet+SagB for co-expression. Strategies to overcome this could 
include the use of temperature-cycle ligation strategy created by Lund et al. (12).  
5.3 MATERIALS AND METHODS 
PROTEIN PRODUCTION AND CRYSTALLIZATION 
All experiments for transformation, overexpression, isolation and crystallization 
utilized the strategies outlined in Chapter 1, pages 27-30. 
PROTEIN REFOLDING AND ISOLATION 
After initial attempts at isolation proved unsuccessful at producing a significant 
amount of protein for crystal screening. The a small portion of the insoluble fraction (~10 
mg) was dissolved in 6 M Guanidine HCl or 8 M Urea and each of the Sag proteins were 
re-isolated by IMAC in denaturing conditions. 
After elution of the unfolded protein from the column, approximately 100 µL of 
eluate, in denaturing conditions, was added to 10 mL of the re-folding conditions reported 
in Table 5.1.  This approach is called fast dilution re-folding and was reported to be 
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successful for some proteins (13, 14). After the dilution the solution of the protein was 
stirred overnight (~12 hrs) at room temperature.  The refolding condition that produced the 
least of protein precipitate were selected for further experiments. The solution(s) identified 
during these experiments were used to store the protein and perform gel filtration 
purification. After gel filtration, the protein was checked for purity using SDS-PAGE, 
concentrated and used for crystallization experiments.  
MOLECULAR CLONING OF SAGBCD COMPLEX 
Due to the instability of the Sag proteins, it was assumed that through co-expression 
of the proteins, there could be an increase in the stability of the individual proteins as a 
result of possible stabilizing interactions from complex formation. To accomplish this, two 
strategies were enacted; in Strategy 1 the goal was to introduce sagB, sagD into a single 
plasmids and allow it to be co-expressed with sagC. More specifically, one of the plasmids 
would be engineered to co-express SagB and SagD in a plasmid encoding for Ampicillin-
resistance (the pETDuet™ plasmid), while SagC would be expressed on a separate plasmid 
encoded to promote Kanamycin resistance (Figure 5.15). In Strategy 2, the intention would 
be to co-express each plasmid individually, within the same organism.  Each plasmid would 
contain genetic information for different antibiotic resistance, more specifically, SagB 
would be introduced into a plasmid encoding for Ampicillin-resistance, SagC into a 
plasmid encoding for Kanamycin-resistance, and SagD into a plasmid encoding for 
Chloramphenicol resistance (Figure 5.16).  
These protocols were adapted from published strategies from Tolia and Joshua-Tor 




Plasmids for SagB, SagD, and pET-DUET (Novagen, Madison, WI) were 
transformed into competent DH5 alpha cells (NEB, Ipswich, MA) using the heat/ cold 
shock technique (16). A single colony from each transformation experiment was cultured 
in 5 mL of LB media, with respective antibiotic, for 12-16 hours. Each culture was 
centrifuged to at 3900 g for 10 min and the culture media was discarded. Plasmids were 
extracted and concentrated according to the protocol for the GeneJET plasmid Miniprep 
kit (Thermo Scientific, Waltman, MA).  Plasmid concentrations were determined by UV 
spectroscopy, and eventually stored at -20 ºC for future testing.  
For the introduction of SagB into the pETDuet™ plasmid, restriction enzymes NdeI 
and XhoI were identified for excision and experiments were conducted in accordance with 
protocol from NEB Double digest finder (17). At experiment completion, agarose gel 
electrophoresis was used to isolate cut pETDuet™plasmid and excised SagB. Upon 
identification of SagB and pETDuet™, they were cut out of the gel and made soluble 
through the use of the Plasmid GeneJET Gel extraction Kit (Thermo Scientific, Waltman 
MA). Ligation experiments were prepared in 6, 20 µL experiments. Experiment conditions 
all contained a standard, 2 µL of SagB DNA, 2 µL of buffer, and 1 µL of T4 DNA Ligase 
(NEB). Variation in the experiment preparation occurred with increasing volumes of 
plasmid DNA in the following consecutive volumes, 0.5 µL, 1 µL, 1.5 µL, 2 µL, 2.5 µL, 
and 3 µL, with accommodating amounts of nuclease-free water to achieve a 20 µL total 
volume. Ligation experiments were run overnight at 18 °C. Due to low recovery from the 
gel ligation, experiments went directly to the transformation protocol. Any colony growth 
that was obtained was cultured and confirmed by sequencing.  
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SagD, within the pjexpress411 plasmid (DNA 2.0, Menlo Park CA), did not contain 
useful restriction sites for introduction into the pETDuet™system, so new restriction sites 
had to be created.   Primers for restriction sites EcoRI and NdeI created and were introduced 
by PCR using the following protocol: Cycle # 1: 98 °C: 2 min, Cycle # 2-33: Denature- 98 
°C, Anneal-65 °C- 55 °C: 30 sec, Extend-72 °C:1 min, 30 sec, Final Cycle (# 34): 
Denature-98 °C, Anneal-65 °C, Extend 72 °C, 5 min, Final Hold at 4 °C.   Primer 
information is shown in Figure 5.17.  
Strategy 2:  
In strategy 2, SagB (Ampicillin-resistant) and SagC (Kanamycin-resistant) 
plasmids were introduced into BL21 (DE3) cells, simultaneously, using the heat shock/ 
cold shock method (16).  Cells were cultured and grown on Amp/Kan resistant plates for 
confirmation. SagBC cells were then made competent using a calcium chloride method 
adapted from Sambrook et al. (18). SagD, which has Kanamycin resistance in the pJexpress 
plasmid, had to be transplanted into another antibiotic-resistant plasmid to confirm 
successful transformation into the new SagBC strain. The SagD insert was cut from the 
pJexpress41 plasmid (DNA 2.0, Menlo Park, CA) using the restriction enzymes XhoI and 
XbaI and transferred into a pHSG396 plasmid which contained genomic information for 
Chloramphenicol resistance. The transfer of the insert was conducted utilizing the same 
techniques outlined in Strategy 1. The introduction of SagD insertion into the Cam-res 
plasmid was confirmed by sequencing (Eton Biosciences, RTP, NC). The plasmid was 
introduced into the SagB/C competent cells, and introduction was confirmed by the growth 
of the bacteria on the Kan/Amp/Cam resistant plates. 
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OTHER COMPUTATIONAL METHODS 
 All Other Computational Methods are consistent with what was described in 




5.4 TABLES AND FIGURES 
Table 5.1: Conditions used for protein re-folding (14). 
Condition  Components 
1  0.5 M L-arginine, 0.05 M MES (pH 6.0), 0.05 M NaCl, 0.05 M KCl 
 
2  0.5 M L-arginine, 0.05 M Tris (pH 8.0), 0.05 M NaCl, 0.05 M KCl 
 
3  0.5 M L-arginine (pH 8.5) 
 
4  0.5 M guanidine HCl, 0.05 M MES (pH 6.0) 
 
5  0.5 M guanidine HCl,0.05 M Tris (pH 8.0) 
 
6  0.25 M KCl, 0.05 M HEPES (pH 6.0) 
 
7  0.4 M sucrose, 0.05 M MES (pH 6.0) 
 
8  0.4 M sucrose, 0.05 M Tris (pH 8.0) 
 
9  1% w/v PEG 3350, 0.05 HEPES (pH 7.5), 0.01 M NaCl, 0.01 M KCl 
 
10 1% w/v beta-cyclodextrin, 0.05 HEPES (pH 7.5), 0.01 M NaCl, 0.01 M KCl 
 
11  0.5 M glycine ethyl ester HCl, 0.05 HEPES (pH 8.0), 0.01 M NaCl, 0.01 M 
KCl 
 
12  0.5 M NDSB-221, 0.05 HEPES (pH 8.0), 0.01 M NaCl, 0.01 M KCl 
 
13  0.5 M NDSB-221, 0.05 HEPES (pH 8.0), 0.01 M NaCl, 0.01 M KCl 
 
14  0.5 M L-arginine (pH 8.5) , 0.01 M MgCl2, 0.01 M KCl 
 
15  0.5 M L-arginine (pH 8.5), 0.01 M CaCl2, 0.01 M KCl 
 






Figure 5.1: Overview of predicted SagBCD complex reaction. a schematic of the proposed 
activity of the proteins of the SagBCD complex (3). The FxxxB region of SagA is described 
as a possible recognition sequence by SagE (1). The FxxxB corresponds to phenylalanine 





Figure 5.2: Schema of the proposed enzymatic activity of SagB and SagC.  A schematic of 
the proposed activity of SagB and SagC (3). SagC is considered to operate as a 
cyclodehydratase forming the ring (3). SagB is suggested to function as a dehydrogenase, 
removing hydrogen from the ring with the assistance of flavin mononucleotie (FMN) to 






Figure 5.3:  SagB SDS-PAGE isolation result. This image shows SDS-PAGE results 
confirming the isolation of SagB. Total volume obtained: ~ 1 mg/ mL. Sample volume 







Figure 5.4:  SagC SDS-PAGE isolation result. SDS-PAGE results confirming the isolation 
of SagC. Total volume obtained: ~ 1 mg/ mL. Sample volume applied to well: 10 µL. 
Isolated SagC is marked with an asterisk. The molecular weights for marker poteins are 






Figure 5.5: SagD SDS-PAGE isolation result. SDS-PAGE results confirming the 
isolation of SagD. Total volume obtained: 1 mL. Concentration: ~1 mg/mL. Sample 








Figure 5.6: SagG SDS-PAGE isolation result. SDS-PAGE results confirming the 
isolation of SagG. Total volume obtained: 1 mL. Concentration: ~5 mg/mL. Sample 







Figure 5.7: SagD/SagD_DNASU sequence alignment results. Comparison of SagD 





Figure 5.8: Agarose gel result for SagB and pETDuet™ restriction enzyme experiments 
(Strategy 1).  This agarose gel result shows evidence of restriction enzyme activity on the 
pJexpress411 plasmid containing SagB plasmid, and the pETDuet™ plasmid. “SagB (cut)” 






Figure 5.9: Agarose gel result for addition of new restriction sites for SagD (Strategy 1). 
The agarose gel shows evidence of amplification and isolation of the SagD insert with new 






Figure 5.10: Agarose gel result for the SagD and pHSG396 restriction enzyme experiment 
(Strategy 2). The agarose gel presents the successful removal of the SagD insert from the 
pJexpress411 plasmid, as well as, results of the successful excision of the pHSG396 






Figure 5.11: Homology modeling result for SagB. Calculated structure of SagB obtained 
from using PHYRE2. The homology modeling results indicate that SagB may form a 
dimer. The putative dimer is represented in cartoon and surface representations. The 
sequence conservation is mapped on the protein surface representation (blue color 
corresponds to highly conserved residues, while red indicates variable residues). Binding 
sites for FMN (yellow) are highly conserved in term of protein sequence. The structure is 






Figure 5.12: Homology modeling result for SagC. Calculated structure of SagC was 
obtained using PHYRE2. The modeling results also suggests that SagC may form a dimer. 
The putative dimer is represented in cartoon and surface representations. The sequence 
conservation is mapped on the protein surface representation (blue color corresponds to 
highly conserved residues, while red indicates variable residues). The structure is based on 
a complex between E. coli MccB protein and MccA-N7isoASN peptide (PDB code: 






Figure 5.13:  Homology modeling result for SagD. Calculated structure of SagD obtained 
using PHYRE2. The structure is based on structure of heterocyclase TruD from an 
uncultured Prochloron sp. 06037A (PDB code: 4BS9). Similar to the structures above, the 
homology model suggests that SagD may also form a dimer. The putative dimer is 
represented in cartoon and surface representations. The sequence conservation is mapped 
on the protein surface (blue color corresponds to highly conserved residues, while red 
indicates variable residues). AMP and Zn2+ (yellow-AMP / green-Zn2+) positions were also 




Figure 5.14:  Homology modeling result for SagG. Calculated structure of SagG was 
obtained using PHYRE2. The structure is based on a structure of the ABC transporter ATP-
binding protein from Thermotoga maritima (PDB code: 4YER). The homology model 
results predict that SagD is also a dimer with a proposed binding sites for ADP (pink). The 
putative dimer is represented in cartoon and surface representations. The sequence 
conservation is mapped on the protein surface representation (blue color corresponds to 





Figure 5.15: Schematic of SagBCD molecular cloning strategy 1. This is a diagram of 
Strategy 1 for SagBCD co-expression in E. coli. This strategy involves the insertion of two 
plasmids (one expressing for SagB and D, and the other for SagC only) into BL21 (DE3) 
E. coli for co-expression experiments. The experimental design was adapted from Markle 





Figure 5.16: Schematic of SagBCD molecular cloning strategy 2.  This diagram describes 
Strategy 2 for SagBCD co-expression in E. coli. This strategy involves the insertion of 
three individual plasmids (expressing specifically for SagB, SagC, and SagD) into BL21 





Figure 5.17: Schematic of primer design used for restriction site modification of SagD 
(Strategy 1). This diagram displays the strategy for introducing new restriction sites into 
the SagD plasmid prior to insertion of SagD reading frame into pETDuet™. This is done 
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APPENDIX A – DSF LIGAND SCREENING CONDITIONS 
 
Table A.1. Hampton screen additives (DSF)  
(*All solutions also contain 0.1 M Tris (pH 7.5)*)
 
A1 0.1M Barium Chloride 
A2 0.1M Cadmium Chloride 
A3 0.1M Calcium Chloride 
A4 0.1M Cobalt(II) Chloride 
A5 0.1M Copper(II) Chloride 
A6 0.1M Magnesium Chloride 
A7 0.1M Manganese(II) Chloride 
A8 0.1M Strontium Chloride 
A9 0.1M Yttrium(III) Chloride 
A10 0.1M Zinc Chloride 
A11 0.1M Iron(III) Chloride 
A12 0.1M Nickel(II) Chloride 
B1 0.1M Chromium(III) Chloride 
B2 0.1M Praseodymium(III) Acetate 
B3 1M Ammonium Sulfate 
B4 1M Potassium Chloride 
B5 1M Lithium Chloride 
B6 2M Sodium Chloride 
B7 0.5M Sodium Fluoride 
B8 1M Sodium Iodide 
B9 2M Sodium Thiocyanate 
B10 1M Potassium Sodium Tartrate 
B11 1M Sodium Citrate 
B12 1M Cesium Chloride 
C1 1M Sodium Malonate 
C2 0.1M L-Proline 
C3 0.1M Phenol 
C4 30% DMSO 
C5 0.1M Sodium Bromide 
C6 30% 6-aminohexanoic acid 
C7 30% 1,5-diaminopentane 
C8 30% 1,6-diaminohexane 
C9 30% 1,8-diaminooctane 
C10 1M Glycine 
C11 0.3M Glycyl-glycyl-glycine 
C12 0.1M Taurine 
D1 0.1M Betaine HCl 
D2 0.1M Spermidine 
 
D3 0.1M Spermidine x 4HCl 
D4 0.1M Hexammine Cobalt(III) Chloride 
D5 0.1M Sarcosine 
D6 0.1M Trimethylamine HCl 
D7 1M Guanidine HCl 
D8 0.1M Urea 
D9 0.1M β-Nicotinamide Adenine 
D10 0.1M ATP 
D11 0.1M TCEP HCl 
 
D12 0.01M GSH 
E1 0.1M EDTA 
E2 5% Polyvinylpyrrolidone 
E3 30% Dextran Sulfate Sodium Chloride 
E4 40% Pentaerythritol ethoxylate 
E5 10% PEG 3350 
E6 30% D-(+)-Glucose 
E7 30% Sucrose 
E8 30% Xylitol 
E9 30% D-Sorbitol 
E10 12% Myo-inositol 
E11 30% D-(+)-Trehalose 
E12 30% D-(+)-Galactose 
F1 30% Ethylene Glycol 
F2 30% Glycerol 
F3 3M NDSB-195 
F4 2M NDSB-201 
F5 2M NDSB-211 
F6 2M NDSB-221 
F7 1M NDSB-256 
F8 0.15mM CYMAL-7 
F9 20% Benzamidine 
F10 5% LDAO, DDAO 
F11 5% n-octyl-β-D-glucoside 
F12 5% n-dodecyl-β-D-maltoside 
G1 30% Trimethylmine-N-oxide 
G2 30% 1,6-hexanediol 
G3 30% 2-methyl-2,4-pentanediol 
G4 50% PEG 400 
G5 40% Jeffamine M-600 
G6 40% 2,5-hexanediol 
G7 40% 1,3-butanediol 
G8 40% PEG 400 
G9 30% 1,4-dioxane 
G10 30% Ethanol 
G11 30% 2-Propanol 
G12 30% Methanol 
H1 40% 1,4-butanediol 
H2 40% tert-butanol 
H3 40% 1,3-propanediol 
H4 40% Acetonitrile 
H5 40% Formamide 
H6 40% 1-propanol 
H7 5% Ethylacetate 
H8 40% Acetone 
H9 0.25% Dichloromethane 
H10 7% 1-butanol 




Table A.2:  DSF ligand screen 2 
(*All solutions also contain 0.05 M Tris (pH 7.5)*)
A1 0.1M Valine 
A2 0.1M Alanine 
A3 0.1M Arginine 
A4 0.1M Malate 
A5 0.1M Sodium Citrate 
A6 0.1M Threonine 
A7 0.1M Glutamine 
A8 0.1M Isoleucine 
A9 0.1M Succinate 
A10 0.1M Sodium Pyruvate 
A11 0.1M Glucose 
A12 0.1M Lysine 
B1 0.1M Asparagine 
B2 0.1M Homoserine 
B3 0.1M Cytosine 
B4 0.1M Glutamate 
B5 0.1M Proline 
B6 0.1M Taurine 
B7 0.1M Nicotinamide 
B8 0.1M Guanine 
B9 0.1M Glycine 
B10 0.1M Serine 
B11 0.1M Methionine 
B12 0.1M 4-methylcatechol 
C1 0.1M Citrate 
C2 0.1M Nicotinamide 
C3 0.01M Magnesium Chloride 
C4 0.1M Leucine 
C5 0.01M Zinc Chloride 
C6 0.01M Iron(III) Chloride 
C7 0.1M Sodium Pyrophosphate 
C8 0.1M Thymine 
C9 0.1M Sucrose 
C10 0.01M Calcium Chloride 
C11 0.1M Spermidine 
C12 0.1M 2,6-Pyridine dicarboxylic acid methyl 
ester 
D1 0.1M Tryptophan 
 
D2 0.1M Sodium Cholate 
D3 0.1M Sodium Pyrophosphate 
D4 0.01M Manganese(II) Chloride 
D5 0.1M 2,6-Pyridine dicarboxylic acid ethyl 
ester 
D6 0.1M Aspartate 
D7 0.1M Adenine 
D8 0.1M Xylitol 
D9 0.01M Cobalt(II) Chloride 
D10 0.1M 2,6-Pyridine dicarboxylic acid 
 
 
D11 0.1M Phenylalanine 
D12 0.1M Uracil 
E1 0.1M Mercaptosuccinate 
E2 0.1M γ-amino-butyric acid 
E3 0.1M 8-hydroxy-2-quinole carboxylic acid 
E4 0.1M Pimelic acid 
E5 0.1M Sodium Benzene 1,3-disulfonate 
E6 0.1M 6-oxo-pipecolinic acid 
E7 0.1M Kanamycin 
E8 0.1M 5-amino-isophthalic acid 
E9 0.1M Chelidanic acid 
E10 0.1M 2-pyridine sulfonic acid 
E11 0.1M 2-proline 
E12 0.1M Gly-gly 
F1 0.1M 3,3',5,5'-tetracarboxyl 
diphenalmethane 
F2 0.1M 5-nitrofuroic acid 
F3 0.1M 4,5-dibromo-2-furoic acid 
F4 0.1M 5-sulfoisophthalic acid 
F5 0.1M Betaine 
F6 0.1M isocitric acid lactone 
F7 0.1M 3-aminobenzene sulfonic acid 
F8 0.1M Chelidonic acid 
F9 0.1M 1,3,5-benzene tricarboxylic acid 
F10 0.1M isocitric acid 
F11 0.1M p-coumaric acid 
F12 0.1M 2,5-thiophene dicarboxylic acid 
G1 0.1M Phosphoserine 
G2 0.1M Tartaric acid 
G3 0.1M Arabinose 
G4 0.1M Chloramphenicol 
G5 0.1M Naringin 
G6 0.1M Caffeic acid 
G7 0.1M 2,4-pyridine dicarboxylic acid 
G8 0.1M 2,3-pyridine dicarboxylic acid 
G9 0.1M 3,5-pyridine dicarboxylic acid 
G10 0.1M 2,5-pyridine dicarboxylic acid 
G11 0.1M Tyrosine 
G12 0.1M Rutin 
H1 0.1M Morin 
H2 0.01M Copper(II) Chloride 
H3 0.1M Maltose 
H4 0.1M AMP 
H5 0.1M Myo-inositol 
H6 0.1M Ascorbic acid 
H7 0.1M Thiamine 
H8 0.1M Pimelic acid 
H9 0.1M 3-aminobenzene sulfonic acid 
H10 0.1M Melamine 
H11 0.1M 2,5 FDC 




Table A.3: DSF ligand screen 3 
(*All solutions also contain 0.1 M Tris (pH 7.5)*) 
 
A1 30% Methanol 
A2 30% Ethanol 
A3 30% DMSO 
A4 40% Acetone 
A5 30% Glycerol 
A6 30% Ethylene Glycol 
A7 0.1M Bromosuccinic acid 
A8 0.1M Cytidine 
A9 0.1M Cytidine in 100% Ethanol 
A10 0.1M Sodium Deoxycholate 
A11 0.1M Sodium Chloride 
A12 0.1M Trimesic acid 
B1 0.1M Histidine HCl 
B2 0.1M 1,4-butanediol 
B3 0.1M Neopentyl Alcohol 
B4 0.1M Cadmium Chloride 
B5 0.1M Malonic acid 
B6 0.1M 3,4-dihydroxybenzoic acid 
B7 0.1M CHES 
B8 0.1M MOPS 
B9 0.1M L-norvaline 
B10 0.1M 1,6-hexanediol 
B11 0.1M Lanthanum Chloride Heptahydrate 
B12 0.1M Vanillin 
C1 0.1M Kanamycin Sulfate 
C2 0.1M N,N-dimethylglycine 
C3 0.1M Salicylic acid 
C4 0.1M 3-hydroxy-2-naphthoic acid 
C5 0.1M Tris(hydroxymethyl)aminomethane 
C6 0.1M CAPS 
C7 0.1M Ethylene Glycol 
C8 0.1M Chloroquine 
C9 0.1M Potassium Thiocyanate 
C10 0.1M Fast Garnet GBC Salt 
C11 0.1M N,N-dimethyldecylamine-N-oxide 
C12 0.1M 1,4-butanediphosphonic acid 
D1 0.1M Lithium Acetate 
D2 0.1M Magnesium Nitrate 
D3 0.1M Fast Violet B Salt 
D4 0.1M β-NAD 
D5 0.1M α-lactose monohydrate 
D6 0.1M Guanidine Thiocyanate 
D7 0.1M Sodium Bisulfate 
D8 0.1M BOC-L-serine 
D9 0.1M Glutathione (reduced) 
D10 0.1M PIPES 
D11 0.1M Sodium Bicarbonate 
D12 0.1M Thiourea 
E1 0.1M α-naphthyl acid phosphate 
E2 0.1M Streptomycin Sulfate 
E3 0.1M Hexamine Cobalt(III) Chloride 
E4 0.1M Magnesium Sulfate 
E5 0.1M Lithium Sulfate 
E6 0.1M 4-dimethylaminopyridine 
E7 0.1M S-(-)-2-bromopropionic acid 
E8 0.1M O-phospho-DL-serine 
E9 0.1M Nickelous Acetate 
E10 0.1M Tetraamine Copper(II) Sulfate 
E11 0.1M Potassium Tetrachloroplatinate 
E12 0.1M Ammonium Cerium(IV) Nitrate 
F1 0.1M Chromium Acetate 
F2 0.1M Trifluoroacetic acid Silver Salt 
F3 0.1M Nicotinic acid 
F4 0.1M Trimethyl Lead Acetate 
F5 0.1M Propylenediphosphonic acid 
F6 0.1M Nickel Sulfate 
F7 0.1M Tetraethylpropylene-1,3-diphosphonic 
acid 
F8 0.1M 1,6-hexane bis-phosphonic acid 
F9 0.1M Cesium Fluoride 
F10 0.1M Strontium Nitrate 
F11 0.1M Cobaltous Sulfate 
F12 0.1M Glutathione 
G1 0.1M Cerous Chloride 
G2 0.1M Sodium Molybdate(III) dehydrate 
G3 0.1M Thallium(I) Nitrate 
G4 0.1M Cesium Chloride 
G5 0.1M Iodoacetamide 
G6 0.1M Phosphonoacetic acid 
G7 0.1M 2,6-naphthalenedisulfonic acid 
disodium salt 
G8 0.1M Propionic acid 
G9 0.1M Calcium Acetate 
G10 0.1M 1,1,3,3-tetramethylurea 
G11 0.1M Adonitol 
G12 0.1M Nicotinamide 
H1 0.1M GMP 
H2 0.1M Cacodylic acid 
H3 0.1M Calcium Formate 
H4 0.1M Lithium Citrate 
H5 0.1M Imidazole 
H6 0.1M Lithium Chloride 
H7 30% Dextrose 
H8 0.1M Sodium Sulfate 
H9 0.1M Thymidine 
H10 0.1M Potassium Hydrogen Phthalate 
H11 0.1M Ferrous Sulfate 
H12 0.1M Hydroxylaminohydrochloride 
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Table A.4:  DSF ligand screen 4  
 (*All solutions also contain 0.1 M Tris (pH 7.5)*) 
 
A1 0.1M ADA (N-2-acetamide-2-iminodiacetic 
acid) 
A2 0.1M trans-4,5-dihydroxy-1,2-dithiane 
A3 0.1M 1-naphthalene acetic acid 
A4 0.1M β-alanine 
A5 0.1M Potassium Chloride 
A6 0.1M Cerium(III) Chloride Heptahydrate 
A7 0.1M Lithium Fluoride 
A8 0.1M 5,5'-dithiobis(2-nitrobenzoic acid) 
A9 0.1M 1,2,4,5-benzenetetracarboxylic acid 
A10 0.1M Cyclohexylsuccinic acid 
A11 0.1M 6-(methoxycarbonyl) picolinic acid 
A12 0.1M CHAPS 
B1 0.1M trans-cinnamic acid 
B2 0.1M Sulfonic acid 
B3 0.1M Sodium 3-sulfobenzoate 
B4 0.1M 8-anilino-1-naphthalene sulfonic acid 
B5 0.1M N-bromosuccinimide 
B6 0.1M Terephthalic acid 
B7 0.1M Chlorosuccinic acid 
B8 0.1M Guanidine HCl 
B9 2% Triton-X114 
B10 0.1M L-serine 
B11 0.1M Dextrose Anhydrous 
B12 0.1M Sodium Tartrate Dihydrate 
C1 0.1M Sodium Acetate Trihydrate 
C2 0.1M PEG 400 
C3 10% Poly(vinyl Alcohol) 
C4 0.1M 1,2-dihydroxybenzene 
C5 0.1M Sodium Malonate Dibasic 
Monohydrate 
C6 0.1M 5-aminovaleric acid 
 
C7 0.05M PEG 8000 
C8 0.1M PEG 200 
C9 0.1M NDSB-221 
C10 0.1M NDSB-201 
C11 0.1M 2,2-dimethylsuccinic acid 
C12 0.05M PEG 6000 
D1 0.1M PEG 4000 
D2 0.1M NDSB-256 
D3 0.1M Glycerol 
D4 0.1M MES Free Acid Monohydrate 
D5 0.1M PEG 2000 MME 
D6 0.1M PEG 5000 MME 
D7 0.1M NDSB-195 
D8 0.1M Phthalic acid 
D9 0.1M 2-methyl-2,4-pentanediol 
D10 0.1M PEG 3350 
D11 0.1M PEG 1000 
D12 0.1M 2-hydroxy-2-(2-isopropoxy-2-
oxoethyl) succinic acid 
E1 0.1M 6-(ethoxylcarbonyl) Picolinic acid 
E2 0.1M EDTA 
E3 0.1M Potassium Sulfate 
E4 0.1M Sodium Carbonate 
E5 0.06M N-bromosuccinic acid in 40% 
Acetone 
E6 0.07M Thymol in 30% Ethanol 
E7 0.07M 2-adamantanone in 30% Methanol 
E8 0.07M N-bromosuccinic acid in 30% DMSO 
E9 0.01M 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) 
E10 0.07M Sodium Tetraborate in 30% Ethylene 
Glycol 
E11 0.1M Mellitic acid 
E12 0.1M methyl-6-hydroxymethyl-2-
carboxylate pyridine 
F1 0.07M Decanoic acid in 30% Ethanol 
F2 0.01M Tetrasodium Pyrophosphate 
F3 0.07M Thymine in 30% Methanol 
F4 0.01M Calcium Gluconate 
F5 0.01M D-2-phosphoglyceric acid 
F6 0.07M Hexadecyltrimethylammonium 
bromide in 30% Ethanol 
F7 0.07M 1,3-dicyclohexyl-carbodiimide in 
30% Ethanol 
F8 0.01M Asparagine 
F9 0.01M Calcium Sulfate 
F10 0.07M 2,4-dibromophenol in 30% Ethanol 
F11 0.01M Adenine 
F12 0.07M 3-amino-4-hydroxybenzoic acid in 
30% Ethanol 
G1 0.06M 3-amino-4-hydroxybenzoic acid in 
40% Acetone 
G2 0.01M Phenylurea 
G3 0.06M Chloramphenicol in 40% Acetone 
G4 0.07M Thymine in 30% DMSO 
G5 0.06M 3-indoleacetic acid in 40% Acetone 
G6 0.07M Melamine in 30% Glycerol 
G7 0.07M 5-iodosalicylic acid in 30% Ethanol 
G8 0.07M 4-aminobiphenyl in 30% DMSO 
G9 0.01M Magnesium Citrate 
G10 0.07M Caffeine in 30% Ethanol 
G11 0.07M Quinine HCl in 30% Ethanol 
G12 0.07M Rhodanine in 30% Ethanol 
H1 0.1M (2R,6S)-2,6-piperdinedicarboxylate 
H2 0.1M 8-aminooctanoic acid 
H3 0.1M O-phospho-L-serine 
H4 0.1M Diphenylamino-4-sulfonic acid 
H5 0.1M Phytic acid 
H6 0.1M TCEP HCl 
H7 0.01M Samarium Sulfate 
H8 0.01M Dibutylthiourea 
H9 0.07M 2,6-dibromophenol in 30% Ethanol 
H10 0.07M Kinetin in 30% DMSO 
H11 0.07M 1-phenyl-2-thiourea in 30% Ethanol 
H12 0.01M Thallium Chloride 
 
